Study on Association between Serum Bilirubin and Acute Ischemic Stroke and Its Prognostic Significance by Ramya, A
STUDY ON ASSOCIATION BETWEEN SERUM 
BILIRUBIN AND ACUTE ISCHEMIC STROKE 
AND ITS PROGNOSTIC SIGNIFICANCE  
 
 
A Dissertation Submitted to 
THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY 
CHENNAI 
 
 
In Partial Fulfilment of the Regulations 
For the Award of the Degree of 
M.D. (GENERAL MEDICINE) - BRANCH – I 
 
 
 
 
 
 
GOVERNMENT KILPAUK MEDICAL COLLEGE 
CHENNAI 
APRIL – 2015 
 
 
 
 
BONAFIDE CERTIFICATE 
 
This is to certify that “STUDY ON ASSOCIATION BETWEEN 
SERUM BILIRUBIN AND ACUTE ISCHEMIC STROKE AND ITS 
PROGNOSTIC SIGNIFICANCE” is a bonafide work done by  
Dr. RAMYA. A, Post graduate student, Department of General 
Medicine, Kilpauk Medical College, Chennai-10, under my guidance and 
supervision in partial fulfilment of rules and regulations of the Tamil 
Nadu Dr. M.G.R Medical University, for the award of M.D. Degree 
Branch I (General Medicine) during the academic period from May 2012 
to April 2015.   
 
 
 
 
  
Prof. Dr.R.Sabaratnavel M.D.                     
Professor and HOD,                                                                
Department of Medicine, 
Kilpauk Medical College, 
Chennai 
   
Prof. Dr.S.Ushalakshmi  M.D. 
FMMC.                                                
Professor and Unit Chief, 
Department of Medicine,  
Kilpauk Medical College,                                                                              
Chennai
 
 
 
 
Prof. Dr.N.Gunasekaran M.D., D.T.C.D 
The DEAN 
Govt. Kilpauk Medical College 
Chennai - 600 010 
 
  
DECLARATION 
 
I solemnly declare that this dissertation  “STUDY ON 
ASSOCIATION BETWEEN SERUM BILIRUBIN AND ACUTE 
ISCHEMIC STROKE AND ITS PROGNOSTIC SIGNIFICANCE”  
was prepared by me at Government Kilpauk Medical College and 
Hospital, Chennai, under the guidance and supervision of  
Prof. Dr. S. Ushalakshmi M.D., FMMC, Professor and Unit Chief, 
Department of Internal Medicine, Government Kilpauk Medical College 
and Hospital, Chennai. 
           This dissertation is submitted to The Tamil Nadu Dr. M.G.R. 
Medical University, Chennai in partial fulfilment of the University 
regulations for the award of the degree of M.D. Branch I (General 
Medicine). 
 
 
 
 
Place: Chennai-10      Dr. RAMYA.A 
Date: 
 ACKNOWLEDGEMENT 
 
At the outset, I would like to thank my beloved Dean, Kilpauk 
Medical College, Prof. Dr. N.Gunasekaran, M.D., D.T.C.D., for his 
kind permission to conduct the study in Kilpauk Medical College. 
I would like to thank my former Dean, Kilpauk Medical College, 
Prof. Dr. P.Ramakrishnan M.D, D.L.O, for his initial permission to 
conduct the study in Kilpauk Medical College. 
I would like to acknowledge, Prof. Dr. R,Sabaratnavel, M.D., 
Professor and Head of the Department of medicine, Kilpauk Medical 
College and Govt.Royapettah Hospital for his supportiveness and 
guidance to my study work. 
With extreme gratitude, I express my indebtedness to Prof. Dr. 
S.Ushalakshmi M.D., FMMC., my Unit Chief and Professor of 
Medicine for her continuous motivation, affectionate guidance, valuable 
suggestions, sympathetic, helping nature and encouragement enabled me   
to complete the dissertation. 
I would like to wholeheartedly thank Prof. Dr. G Balan M.D., 
Former Professor and Head, Department of Internal Medicine, Kilpauk 
Medical College Hospital for his encouragement and guidance during the 
study. 
 I also express my special thanks to Prof. Dr. T.Ravindran M.D., 
DNB., Unit Chief for his valuable advice. 
I also express my sincere thanks to Dr.D.Venkateswarlu M.D., 
Registrar, Department of Internal Medicine, Kilpauk Medical College, for 
his motivation and continuous guidance. 
I am extremely thankful to my unit Assistant Professors, 
Dr.M.Bhathragiri M.D. and Dr.A.Marimuthu M.D., for their valuable 
suggestions and guidance. 
I would always remember with extreme sense of thankfulness for 
the co-operation and criticism shown by my fellow post graduate 
colleagues and friends. 
I also extend my thanks to all the laboratory technicians for their 
valuable support throughout my dissertation work. 
I would like to take this opportunity to show gratitude to my family 
for their never ending support in completing this thesis. 
I also extend my thanks to my friend Dr. C. Palanivel M.D., for 
his valuable suggestions and timely guidance. 
Finally, I wholeheartedly thank all my patients for their active co-
operation in this study, without whom this would not have become a 
reality. 
  
 TABLE OF CONTENTS 
 
S.No. CONTENTS PAGE No. 
1 INTRODUCTION 1 
2 AIM AND OBJECTIVES 3 
3 REVIEW OF LITERATURE 4 
4 MATERIALS AND METHODS 60 
5 RESULTS AND ANALYSIS 66 
6 DISCUSSION 100 
7 CONCLUSION 105 
8 BIBLIOGRAPHY 106 
9 
ANNEXURES 
 
 
 ABBREVIATIONS 
 PROFORMA 
 MASTER CHART 
 CONSENT FORM 
ETHICAL COMMITTEE 
APPROVAL CERTIFICATE 
 
115 
116 
117 
123 
 
124 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
ABSTRACT 
BACKGROUND 
Bilirubin as a marker of oxidative stress can be increased in acute 
ischemic stroke. 
OBJECTIVE 
To find any association exists between serum bilirubin level and 
acute ischemic stroke and assess the usefulness of serum bilirubin in 
determining the severity and prognosis of stroke. 
METHODS AND MATERIALS 
Bilirubin and other biochemical parameters were measured in 50 
cases (acute ischemic stroke) and 50 age, sex, comorbid conditions 
matched controls. NIHSS score was assessed at admission and MRS 
score was assessed after 7days of stroke. Serum total bilirubin levels were 
divided into 3 groups <0.6mg/dL,0.7-0.9mg/dL,≥1.0mg/dL. NIHSS score 
was divided into two groups ≥10(Severe Stroke) and <10. MRS score was 
divided into two groups <3(Good Outcome) and ≥3(Poor Outcome). The 
bilirubin level and its association with acute ischemic stroke and its 
correlation with stroke severity and prognosis was analyzed. 
 
RESULTS 
The level of serum total bilirubin and indirect bilirubin was 
significantly higher in acute ischemic stroke patients (p value < 0.001 and 
<0.001 respectively) than in the control group. The level of serum direct 
bilirubin didn’t show any significant correlation.  The level of serum 
total bilirubin (p value 0.0003 and 0.0002 respectively) and indirect 
bilirubin (p value 0.003 and 0.001 respectively) was significantly 
correlated with NIHSS ≥ 10and MRS ≥ 3. 
CONCLUSION 
In this study it was found that serum levels of total and indirect 
bilirubin were increased after acute ischemic stroke. Both serum total 
bilirubin and indirect bilirubin can reflect the severity and prognosis of 
stroke. 
KEYWORDS:BILIRUBIN,ACUTE ISCHEMIC STROKE,SEVERITY, 
PROGNOSIS. 
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INTRODUCTION 
Stroke is the third commonest cause of death across the world. 
Stroke is becoming a very important cause of disability and premature 
death in developing countries like India.  
Over the last few decades, a rise in non communicable diseases 
including stroke has been considered to be related primarily to 
demographic changes and enhanced by the prevalence of the risk factors. 
Bilirubin the final product of heme catabolism was thought to be 
only a waste end-product. However, it is now considered as an 
antioxidant that may have role in the progress of  diseases caused by 
oxidative stress, such as stroke.  
Oxidative stress resulting in the production of free radicals is found 
to be an important mechanism of brain damage in acute ischemic stroke 
and  the bilirubin being  an antioxidant,its synthesis  is induced in 
response to oxidative stress .Bilirubin can reflect the severity of oxidative 
stress.  
In the study ,we aimed to find the association of serum bilirubin 
with acute ischemic stroke.     
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Various studies conducted during the acute phase of  ischemic 
stroke   found inverse relationship between serum bilirubin and positive 
outcomes in stroke patients and bilirubin can act as marker of oxidative 
stress. 
Yun Luo et al (2012) reported that both direct bilirubin and total 
bilirubin can reflect the severity of ischemic stroke. 
Sandra Pineda et al (2008) reported an association between higher 
direct bilirubin on admission  and greater stroke severity
1
. 
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AIM AND OBJECTIVES OF THE STUDY 
 
1. To study the association of serum bilirubin with acute ischemic stroke. 
2. To assess the usefulness of serum bilirubin in determining the severity 
and prognosis of ischemic stroke. 
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REVIEW OF LITERATURE 
BILIRUBIN 
Formation 
Bilirubin is formed by the breakdown of   heme present in various 
forms which includes hemoglobin, myoglobin, peroxidase, catalase, 
tryptophan pyrrolase and cytochromes. Of these hemoglobin is the major 
source of bilirubin of around 80%
56
. 
The catabolism of heme is carried out by the complex enzyme 
system called hemeoxygenase. By the time the heme reaches this 
oxygenase system, the iron got oxidized to ferric form constituting hemin. 
In this system heme is formed again by reduction with NADPH. Oxygen 
is added to the alpha methylene bridge present between pyrroles I and II 
of the porphryin with the help of NADPH. Similarly ferric iron is formed 
by the oxidation of ferrous iron. On consequent addition of oxygen, there 
will be production of ferric iron, CO and also biliverdin which results 
from the splitting of tetrapyrin ring. 
In mammals bilirubin is formed by the reduction of methyne bridge 
present between pyrrole III and IV in biliverdin with the help of the 
enzyme biliverdin reductase. 
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FIGURE 1: BILIRUBIN FORMATION  
 
 
 
 
6 
 
Conjugation 
Bilirubin is non polar and is being converted to polar form in 
hepatocytes by the addition of glucuronic acid and this is called 
conjugation.  
Conjugation can use polar molecules other than glucuronic acid 
(ex:sulphate). This process is catalyzed by specific glucuronosyl 
transferase(B-UGT) present chiefly in endoplasmic reticulum which uses 
UDP-glucuronic acid as the glucuronosyl donor. Bilirubin 
monolglucuronide is an intermediate and gets converted to bilirubin 
diglucuronide which form the major form of bilirubin in bile, whereas in 
pathological conditions bilirubin monoglucuronide are the predominant 
form in plasma. Bilirubin-UGT can be induced by number of drugs. 
Bilirubin is secreted into the bile by an active transport mechanism which 
is the rate limiting step is hepatic bilirubin metabolism. This process is 
mediated by the MRP-2 (Multidrug resistance like protein-2). The 
transport of conjugated bilirubin is inducible by the same drugs that can 
induce the conjugation of bilirubin. 
Conjugated bilirubin is reduced   to urobilinogen by intestinal 
bacteria. On reaching the terminal ileum and the large intestine, the 
glucuronide present in the conjugated bilirubin is removed by specific 
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bacterial enzyme (Beta-Glucuronidases) and is subsequently reduced by 
fecal flora to colorless tetrapyrrole compounds called  urobilinogens. 
FIGURE 2: BILIRUBIN METABOLISM 
 
A small fraction of urobilinogen is reabsorbed in the terminal 
ileum and the large intestine and re-excreted through the liver which is 
called as called enterohepatic urobilinogen cycle .Under pathological 
conditions, like liver disease or excess bilirubin production, urobilinogen 
may be excreted in urine. Most of the urobilinogens in the colon are 
oxidized to urobilins colored one and are excreted in the feces .Oxidation 
of residual uribilinogen to urobilins cause darkening of feces on standing 
in air. 
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STROKE EPIDEMIOLOGY                     
Stroke incidence and also mortality are increasing as a result of 
modernization and increased life expectancy. Worldwide, each year 15 
million people suffer from stroke
2
. Of those one third die and one third 
are left permanently disabled.
3
  
In developing countries there is decreasing trend of infectious and 
malnutrition related diseases, whereas stroke incidence is increasing in 
recent decades as a result of dietary changes, decreased physical activity, 
and increased tobacco use. 
It is estimated that by 2040, in low and middle income countries 
around billion adults aged 65 years or older will be at risk for stroke
4
. In 
addition to the age, hypertension and tobacco use are the major risk 
factors worldwide. 
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MAJOR TYPES OF STROKE 
Stroke occurs as a result of  disruption of  blood flow to  a part of  
brain either because  of  blood vessel occlusion  as  in  acute ischemic 
stroke (AIS) or  blood vessel rupture causing bleeding  either into  the 
brain (Intracerebral hemorrhage-ICH) or around the brain (subarachnoid 
hemorrhage -SAH).  
 
FIGURE 3: ISCHEMIC STROKE & HEMORRHAGIC STROKE 
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STROKE DEFINITIONS 
Stroke is defined as the clinical syndrome of rapid onset of cerebral 
deficit (usually focal) lasting more than 24 hours or leading to death, with 
no apparent cause other than a vascular one.   
Completed stroke is defined as the deficit which becomes maximal 
within 6 hours.  
Stroke-in-evolution is defined as the progression of clinical 
symptoms and signs over first 24 hours.  
In minor stroke patients usually recovers without significant 
neurological deficit within a week.  
Transient ischemic attack   (TIA)   don’t cause permanent brain 
damage and symptoms resolves spontaneously.  
In   TIA   neurological symptoms lasts less than 24 hours,   but the 
duration of most TIAs is between 5 and 30 minutes.  
TIA is   a warning    sign indicating that a stroke may occur at any 
time consequently. 
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RISK FACTORS OF STROKE 
 
TABLE 1: NON MODIFIABLE AND MODIFIABLE RISK FACTORS OF 
STROKE
 5
 
Non Modifiable Modifiable- well documented 
 Gender 
 Age  
 Genetics 
 Race/ethnicity 
 Low birth weight 
 
• Cigarette Smoke 
• Physical Activity 
• Exposure to Poor diet 
• Diabetes 
• Hypertension 
• Dyslipidemia 
• Atrial fibrillation 
• Carotid artery stenosis  
• Postmenopausal hormone  
therapy 
• Sickle cell disease 
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TABLE 2: ISCHEMIC STROKE - ARTERIAL ETIOLOGIES
6
 
1. Thrombosis 2. Embolism 3. Luminal 
Obstruction 
• Atherosclerotic plaque 
• Lipohyalinosis of small 
vessel 
• Tumor invasion 
• TTP/DIC 
• Antiphospholipid 
antibody syndrome 
• Sickle cell disease 
 
Cardioaortic 
• Cardiac thrombus  
• Cardiac vegetations 
• Cholesterol 
• Tumor 
Artery-to-artery 
• Atheroma fragments 
Decompression illness 
Paradoxical 
• Amniotic fluid  
• Deep venous thrombus 
fragments  
• Cholesterol 
• Air 
Vasculitis  
Vasospasm 
• Subarachnoid 
hemorrhage  
• Meningitis 
• Drug-induced  
 Extrinsic artery 
compression 
• Masses  
• Herniation 
Non inflammatory 
vasculopathy 
• Sickle cell disease 
• Migraine  
• Burger’s disease 
• Fibromuscular 
dysplasia  
• CADASIL 
• Moyamoya disease 
Angiotrophic 
lymphoma 
• Lymphomatoid 
granulomatosis 
4.Systemic 
Hypoperfusion 
• Massive MI 
• Shock 
• Cardiac arrhythmia 
• Severe hypotension 
• Hyperviscosity 
syndrome 
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FIGURE 4: MECHANISMS OF VESSEL OBSTRUCTION IN ISCHEMIC 
STROKE
7
 
 
1. Embolus arising from a distant site causing occlusion of intracranial 
vessel E.g. from sources such as carotid atherosclerotic plaque or atrial 
fibrillation. 
2. Thrombosis of an intracranial vessel in situ, mainly in the small 
penetrating arteries.  
3. Stenosis resulting in flow reduction of either intracranial or extracranial 
vessels   mainly leading to watershed infarct. 
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ISCHEMIC STROKE - PATHOPHYSIOLOGY 
Ischemic stroke occurs chiefly by 3 mechanisms which include:  
 Thrombosis 
 Embolism and 
 Hypotension (global ischemia).  
But all ischemic strokes need not fall into these 3 categories, there 
are number of other mechanisms causing ischemic stroke. However, the 
most infrequent causes of stroke are those caused by vasospasm 
(migraine, following SAH, hypertensive encephalopathy) and some form 
of “arteritis”.  
THROMBOSIS  
Atherosclerotic lesion is the most common pathological form   of 
vascular obstruction causing thrombotic stroke
8
. Ulcerations, thrombosis, 
calcifications, and intra-plaque hemorrhage are the secondary changes 
that can occur in plaque. The   plaque structure, consistency and 
composition usually determine the tendency of the plaque to get disrupted 
or ulcerated. 
Disruption of endothelium that can occur in the setting of any one 
of these pathological changes can result in a complicated process and 
activation of many destructive vasoactive enzymes.  
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Adhesion and aggregation of platelets to the vessel wall occurs   
resulting in the formation of small nidi of platelets and fibrin. Within one   
hour of the event, leucocytes at the site initiate an inflammatory 
response
9,10
.  
Thrombotic occlusion of a vessel can occur in pathological 
conditions other than atherosclerosis which include clot formation due to 
hypercoagulable state, arteritis (Giant cell and Takayasu), fibromuscular 
dysplasia and vessel wall dissection. 
In contrast to large artery occlusion , occlusion of deep penetrating 
arteries that are 100 to 400 mm in diameter results in lacunar infarcts .  
The commonly affected sites   are pons, basal ganglia and internal 
capsule. 
Lacunar infarct sizes   only about 20 mm in diameter. The small 
arteriole elongates most frequently because of chronic hypertension and 
becomes tortuous and undergoes subintimal dissections and micro-
aneurysms which increase the susceptibility of arteriole to occlusion from 
micro-thrombi.   
Lipohyalinosis resulting from fibrin deposition is the underlying 
pathological mechanism of lacunar infarct. 
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EMBOLISM 
Embolic stroke (ES) results from dislodging of embolus   from 
variety of sources   in the central circulation.  
Apart from atheromatous plaque other sources of embolus in the 
central circulation are fat, air, metastasis, foreign bodies and bacterial 
clumps.  
The most frequent affected sites of emboli are   superficial 
branches of cerebral and cerebellar arteries. Since   80% of the blood 
carried by the large   arteries in the neck goes to the middle cerebral 
arteries, emboli lodges commonly in the middle cerebral artery 
distribution
11
.  
The most important sources of emboli are the cardiac chambers 
(left side) and large arteries (e.g. thrombus from the internal carotid 
artery).                                         
Embolus acts as a vascular irritant and causes vasospasm which 
determines the outcome of the stroke in addition to vascular territory 
which gets affected. The vasospasm need not be limited to the site where 
the embolus seats, it can also   affect   the whole arterial tree.  
Vasospasm is more common in young individuals comparing with 
elderly since they have pliable, less atherosclerotic vessels. 
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 Most of the embolic strokes turn in to hemorrhagic infarction (HI).  
The pathogenesis of this hemorrhagic transformation of an infarct is a 
composite phenomenon which includes 
1. During ischemia both the brain parenchyma and the blood  vessels are 
injured. When the embolus either lyses automatically or breaks and 
moves distally, cerebral blood flow is restored to the ischemic 
microcirculation. This can result in a “red or hemorrhagic infarct, 
whereas poorly perfused are referred to as “pale” or “anemic infarcts.” 
2. Persistent occlusion can also results in bleeding, which indicates that 
hemorrhagic transformation need not always associated with migration of 
embolus. HI on the periphery of infarcts is caused by reperfusion from   
the leptomeningeal vessels forming collateral circulation which can 
reperfuse the ischemic area even when the main vessel is persistently 
obstructed. 
In embolic stroke both hemorrhage and ischemia occurs together. 
Hemorrhagic transformation
12 
of the infarct depends upon  
 Size of the infarct,  
 Collateral circulation richness, and  
 Use of anticoagulants and  thrombolytic agent.  
Large infarctions are associated with a greater incidence of 
hemorrhagic transformation.  
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GLOBAL-ISCHEMIC OR HYPOTENSIVE STROKE 
 
Hypotensive stroke is caused by the marked reduction in systemic 
blood pressure due to any cause. The susceptibility of neurons to 
ischemia is not uniform. The pyramidal cell layer of the hippocampus, the 
Purkinje cell layer of the cerebellar cortex and cerebral gray matter are 
most vulnerable. This is because of the abundance of glutamate in these 
neurons makes them more susceptible to ischemia.  
“Boundary zone” or “Watershed area” is the area between the 
territories of the major cerebral and cerebellar arteries and this is the 
common site affected by the global ischemia.                                                
The most commonly affected site is the parietal-temporal-occipital 
triangle which causes a clinical syndrome consisting of weakness and 
sensory loss predominantly the arm; the face is not affected and speech is 
spared. Watershed infarct constitutes 10% of all ischemic strokes and 
around 40% of these occur in patients having carotid stenosis or 
occlusion
13
. 
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ISCHEMIC STROKE - PATHOGENESIS AT CELLULAR LEVEL 
Ischemia causes a sequence of events that ultimately leads to 
neuronal injury and death irrespective of the mechanism responsible for 
the vessel occlusion
14
. Blood flow reduction decreases the formation of 
high energy phosphates. 
This energy failure results in membrane depolarization and 
uncontrolled discharge of excitatory aminoacids, such as glutamate, in to 
the extracellular space   which is called as excitotoxicity. This excitotoxic 
aminoacid glutamate exerts its action on various receptors e.g. NMDA 
and AMPA, finally  causing calcium overload of neuronal cells  This rise 
in calcium level results in the activation of proteolytic enzymes.  
The activated enzymes degrade both intracellular and extracellular 
structures, and also other enzymes, i.e. cyclooxygenase and 
phospholipase A2 which can form free radicals. Neuronal NO synthase is 
calcium dependent enzyme and form nitric oxide, which can react with 
superoxide generating the highly reactive radical peroxynitrite
15
. 
Ischemia results in expression of proinflammatory genes so that several 
inflammatory mediators are released mainly tumor necrosis factor and 
interleukin 1ß.   
20 
 
In addition, adhesion molecules are also expressed which results in 
binding of neutrophils, monocytes and macrophages with endothelium 
causing microvascular occlusion and the blood cells crosses the vessel 
wall and penetrates in to the brain substance and exerts their 
inflammatory actions. The inflammatory cells can also form free radical. 
FIGURE 5: PATHOGENESIS OF ISCHEMIC STROKE
 
Although excitotoxicity mainly leads to necrosis, there is evidence 
of apoptosis after cerebral ischemia and it has been proposed that both 
necrosis and apoptosis are triggered in parallel during ischemia and that 
the predominance of one mechanism will be determined by specific 
conditions. 
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STROKE SYNDROMES 
Anterior Cerebral Artery Syndromes 
Medial portion of the frontal and parietal lobes are supplied by 
anterior cerebral artery. Infarction of these areas results in contralateral 
hemianesthesia and hemiparesis that affects the leg more than arm/face 
due to the topographic arrangement of the homunculus. 
In addition damage to the medial part of frontal lobe results in 
impairment of behavioral and executive functions which can cause 
abulia
6
.   
Anterior cerebral artery infarcts in dominant hemisphere may 
produce mutism, and whereas in nondominant hemisphere  results  in 
acute confusional state.  
In bilateral ACA  infarcts, severe abulia can be present as akinetic 
mutism along with bladder incontinence. 
 
Middle Cerebral Artery Syndromes 
The remaining frontal and parietal lobes,  are supplied by middle 
cerebral artery which also supplies the superior part of the temporal lobe.  
Stroke affecting the complete territory results in contralateral 
hemiparesis, hemianopia and  hemianesthesia.  Ipsilateral gaze preference 
with attention related frontal lobe dysfunctions results.  
22 
 
In dominant MCA lesions, impairment of language functions 
occurs resulting in motor aphasia with lesions at Broca’s area   which is 
present in the posterior-inferior portion of frontal lobe and as sensory 
aphasia with lesions at Wernicke’s area which is present in the posterior-
superior portion of temporal lobe.  
Injury in the corresponding areas in the nondominant hemisphere 
results in subtle symptoms of language dysfunction  in form of motor and  
sensory aprosodia. There is duplicative damage to sensory, motor, 
executive and language functions areas which  occurs in total  proximal 
MCA occlusions  , by damaging  both cortical representations and basal 
ganglia structures.  
Lesions of the MCA in the distal part or at the  level of bifurcation 
can allow  blood flow in the lenticulostriate arteries sparing  the internal 
capsule and basal ganglia. In this type of lesion the pattern of motor and 
sensory deficits may be incomplete and  irregular and, sparing  the leg 
function especially because of  the topographic arrangement of 
homunculus 
6
. 
Occlusion of superior division of MCA results in syndrome of 
frontal lobe dysfunction, with prominent motor language deficits with 
variable degree of sensory loss. Whereas in inferior division  of MCA 
lesion sensory language  deficit and hemianopsia results. Gerstmann 
23 
 
syndrome includes right-left confusion, acalculia, agraphia and finger 
agnosia which results from lesion in angular gyrus area. 
Posterior Cerebral Artery Syndromes 
The inferior temporal lobe and occipital lobe are supplied by 
posterior cerebral artery. The posterior cerebral artery lesions that don’t 
involve early arterial branches to deep structures cause contralateral 
homonymous hemianopia. Alexia without agraphia is seen in dominant 
hemisphere lesion. In this conditon reading is impaired by the 
combination of  
           1. Impaired connection between the receptive language area and 
contralateral visual field and 
           2. Unilateral visual field defect  
 This occurs as a result of infarction of the fiber tracts passing 
posteriorly through the corpus callosal splenium.  
Anton syndrome is characterized by confabulation, and cortical 
blindness as a result of damage to bilateral occipital lobes.  
The combination of   
                     1. Optic ataxia  
                     2. Occulomotor  apraxia  and  
                     3. Simultagnosia  
  is caused by bilateral PCA infarcts that affect the posterior parietal 
lobes. This condition is  known as Balint syndrome. 
24 
 
TABLE 3: LACUNAR SYNDROMES
16
 
 
 
 
 
LACUNAR SYNDROMES 
Pure Motor Posterior limb of internal 
capsule or thalamus 
Contralateral 
hemiparesis 
Pure sensory Posterior limb of internal 
capsule or thalamus 
Contralateral 
hemisensory loss,,  
Sensory motor Posterior limb of internal 
capsule or thalamus 
Contralateral 
hemisensory 
loss,hemiparesis 
Ataxic 
hemiparesis 
 Pons,basal ganglia,internal 
capsule,Corona radiata,  
 
Contralateral 
hemiparesis with ataxia  
Hemiballismus Subthalamic nucleus lesion  Contralateral 
hemiballismus 
Dysarthria–clumsy 
hand 
Pons,basal ganglia,internal 
capsule,corona radiate 
Contralateral  upper 
limb ataxia and 
dysarthria  
Dejerine-Roussy Thalamus Contralateral hemibody 
pain  with hemisensory 
loss 
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DIAGNOSIS OF STROKE: 
CT Scan 
CT scan images is used to identify or exclude hemorrhage as the 
cause of stroke. CT scans may not detect an infarction in the first 24 to 48 
hours and appears normal in significant percentage .The main 
disadvantage of CT scan are small infarcts, infarcts in the posterior fossa 
may be easily missed because of bone artifact; small infarcts on the 
cortical surface may also be missed
7
. 
CT scans  with contrast enhancement gives more details by 
enhancing   subacute infarcts and allow  clear visualization of venous 
structures . 
CT angiography (CTA) can be performed with administration of  
iodinated contrast which is being coupled with newer multidetector 
scanners thus  iodinated contrast allows better visualization of the 
cervical and intracranial arteries,  and  also  intracranial veins. In this 
method, in one imaging session,  aortic arch, and coronary arteries and  
intracranial veins can be visualized .  
The ischemic penumbra can be detected by contrast study  which 
delineates the area at risk of infarction surrounding the infarction. CT  
without contrast is the  modality of choice in acute stroke  patients 
because of its availability and  speed, and CT perfusion imaging is also an 
useful adjunct.  
26 
 
TABLE 4: CT SCAN FINDINGS
17
 
Time  of Infarct Findings 
 Hyperacute stage :within 12 hrs 
of onset of stroke 
 
• 50-60% of patients shows no  
abnormal findings in this stage. 
• Presence of dense MCA sign. 
• Lenticular nucleus obscuration. 
• Insular ribbon sign. 
• Grey-white interfacement loss.  
Acute stage:last 12 to 24 hrs 
 
• In this stage basal ganglia will  
be hypodense. 
• Sulcal effacement. 
 
Days :1day to 7 days 
• Mass effect. 
• Wedge-shaped hypodense area    
in gray and white matter. 
• Hemorrhagic Transformation. 
Weeks :1-8  • Resolution of  mass effects.  
• Persistence of contrast 
enhancement  
Months to years • Encephalomalacia . Volume 
loss 
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MRI Scan 
MRI clearly shows the  location and extent  of infarction in all 
areas, including  cortical and posterior fossa structure .Regarding 
intracranial  bleed it can identify but is not as sensitive as CT in the 
diagnosis of  hemorrhagic stroke. More reliable and highly précised 
images can be obtained using higher field strength magnets.  Diffusion-
weighted imaging modality is more sensitive than CT for early brain 
infarction or standardMRI
7
. 
MR perfusion imaging can be done using gadolinium contrast.  
Areas with poor perfusion but appearing normal in diffusion sequence are 
considered as ischemic penumbra. Patients having large regions of this 
discrepancy may be taken for acute revascularization procedures. MRA is 
more sensitive in the detection of stenosis of extracranial and intracranial 
parts of  internal carotid arteries.  Comparing with conventional x-ray 
angiography, MRA overestimates the of stenosis severity.  Extracranial  
or intracranial arterial dissection can be visualized by  an sequence named 
as MRI with fat saturation. This technique detects even the clotted blood 
in the vessel wall . 
The disadvantage of MRI are time consuming, cost ineffectiveness, 
less availability and more than these insensitive in detecting blood 
products comparing with CT. Claustrophobia is also an considerable 
disadvantage. 
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Most of the stroke protocols suggest CT because of these issues. 
But for clear description of extent of tissue injury after the acute period 
and distinguishing new from old infarction MRI is superior. In 
diagnosing  TIA  it has considerable significance .It is highly sensitive in 
detecting  new infarction, which is a strong predictor of stroke occurrence 
subsequently. 
TABLE 5: MRI FINDINGS 
Time  of Infarct Findings 
 Immediate Hyperintense on DWI.  
Contrast enhancement. 
Alterations in perfusion. 
<12 hrs Gyral edema, Sulcal effacement.  
Loss of gray-white interfaces (T1). 
 
12 to 24 hrs 
Hyperintensity  (T2). 
Enhancement of meninges adjacent to 
infarct. 
Mass effect. 
1 to 3 days Enhancement of meninges  begins  to 
decline, Hemorrhagic Transformation 
Signal abnormalities on T1WI, T2WI. 
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Cerebral angiography 
Conventional x-ray cerebral angiography is considered as the 
imaging modality for diagnosing atherosclerotic stenoses  and also other 
vascular pathologies such as vasculitis, vasospasm, aneurysms, 
fibromusculardysplasia, arteriovenous fistula, intraluminal thrombi, and 
collateral channels. 
Endovascular techniques may be used in performing balloon 
angioplasty , deploying stents ,treating aneurysms by embolization, and 
also in   opening occluded vessels with mechanical thrombectomy 
devices during acute stroke. 
 In Conventional angiography there are  risks of arterial damage, 
embolic stroke, groin hemorrhage, and renal failure.So it should be 
reserved  where less invasive techniques are inadequate. 
Ultrasound techniques 
B-mode ultrasound image with a Doppler ultrasound  can detect 
and quantify the stenosis   present in  the extracranial part of internal 
carotid artery especially at its origin. Transcranial Doppler (TCD)  can be 
used in assessing flow in main cerebral arteries  and also detecting 
stenosis.In addition TCD can assist thrombolysis and rtPA administration 
. MR angiography can be combined with transcranial and carotid 
ultrasound. 
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Perfusion techniques 
Cerebral blood flow can be quantified by PET and xenon 
techniques but these are not usually applied in clinical practice, being 
used only in research purposes.  
MR perfusion techniques  and Single-photon emission computed 
tomography (SPECT)  are other perfusion techniques which detects 
relative cerebral blood flow. 
 
COMPLICATIONS OF STROKE
5
 
 Urinary tract infection  
 Aspiration Pneumonia   
 Bed sores 
 Deep vein thrombosis 
 Hypoxemia  
 Hyperglycemia 
 Hyponatremia and seizures 
 Constipation  
 Dehydration 
 Frozen Shoulder and subluxation  
 Contractures  
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TREATMENT OF ISCHEMIC STROKE 
Stroke is  an emergency condition irrespective of severity of 
neurological  dysfunction.The priority should be given as to MI and  
serious trauma. Stroke management includes general care, specific 
treatment and treatment of complications. 
First step in the management of stroke is confirmation of diagnosis 
as there are various mimics exists for stroke which includes 
 Seizure 
 Migraine with aura 
 Hypoglycemia 
 Wernicke’s encephalopathy 
 Hypertensive encephalopathy 
 CNS tumor ,CNS abscess 
 Drug toxicity and  
 Psychogenic 
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GENERAL MANAGEMENT OF STROKE  
 Fever and glycemic control 
 Blood pressure management 
 Fluid management  
 Treatment of underlying etiology. 
Blood Pressure Control
17
 
If the systolic  BP is between 185-220 mmHg or diastolic BP  is 
between  105-120 mmHg no need of introducing antihypertensive 
medications unless there are conditions endangers life coexists which 
includes   
 Acute renal failure 
 Acute myocardial infarction/Left ventricular failure. 
 Aortic dissection  
 
 If there is a plan of starting  rtPA therapy   BP >185/110 mmHg should 
be treated. 
If the  Systolic  BP > 220 mmHg, diastolic BP 120-140 mmHg, 
antihypertensive should be immediately administered which includes 
sodium nitroprusside, nicardipine,captopril, nitroglycerine  and labetalol.  
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SPECIFIC TREATMENT  
 Recanalization 
 Anticoagulant 
 Aspirin  
 Neuroprotective treatment 
 Therapeutic hypothermia  
 Hemodilution  
 Craniectomy  
 Rehabilitation 
INTRAVENOUS THROMBOLYSIS 
 Treatment  should be started within 3 hours of stroke onset. 
Treatment by this means can result in complete improvement at 24 hours 
and complete recovery or near normal at 3 months. The major risk is 
symptomatic bleeding in brain. But there is no mortality benefit by this 
treatment. Regimen for IV rt-PA treatment is infusion 0.9 mg/ kg over 1 
hour, 10 % as bolus dose over 1 minute. Anticoagulants and antiplatelet 
agents should not be intiated for first 24 hours of fibrinolysis. 
This is recommended in the setting of early ischemic changes on CT, 
irrespective of its extent. 
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TABLE 6: IV rt-PA INDICATIONS/CONTRAINDICATIONS
7
 
Indication Contraindication 
• Diagnosis of stroke 
clinically 
• Duration ≤3 h 
• CT scan – No 
hemorrhage  
or edema of >1/3 of  
the MCA territory 
• Age ≥18 years 
• Patient or surrogates  
Consent 
• Rapidly improving symptoms 
• Minor stroke  
• Sustained BP >185/110 mm Hg  
inspite of treatment 
• Glucose <50 or >400 mg/dL; 
Platelets <100,000; HCT <25% 
• Heparin use within 48 h and  
prolonged PTT, or elevated INR 
• Prior stroke or head injury in 
preceding 3 months, prior ICH 
• Major surgery in preceding 14 
days 
• GIT bleeding in preceding 21 
days 
• Recent myocardial infarction 
• Coma or stupor 
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Antiplatelet 
Aspirin (325 mg) should be initiated  within 24-48 hours after 
stroke onset. 
Anticoagulant 
All patients with atrial fibrillation of  non valvular origin and 
cardiac disease should be given anticoagulation. Anticoagulation is not 
recommended  in preventing early recurrent stroke, or improving stroke 
outcome,and within 24 hours  of treatment with IV rtPA. The 
contraindications are large infarction,uncontrolled BP,and advanced 
microvascular changes. 
SURGERY 
 Decompressive evacuation of space-occupying infarction in 
cerebellum is effective in preventing and also treating herniation which 
results in brain stem compression.Decompressive surgery is also  
effective for malignant edema of cerebral hemisphere . 
COMPLICATION  MANAGEMENT 
 The major complication includes raised ICT, seizures and 
hemorrhagic transformation. Raised ICT can be managed by non 
pharmacologic measures including head end elevation of bed, avoiding 
hypotonic solution and hypoxia, and hyperventilation. Raised ICT can be 
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treated  pharmacologically by  IV mannitol, IV or oral glycerol,but  
furosemide and steroid is contraindicated. Decompressive surgery is also 
an option. 
MEASUREMENT OF STROKE OUTCOMES 
Stroke severity at presentation predicts stroke outcomes . National 
Institutes of Health Stroke Scale (NIHSS) a  measure of stroke-related 
neurologic deficits,  has been studied extensively  in  various clinical 
trials and found to be an  useful predictor of stroke outcomes. The NIHSS 
is an excellent scale for clinicians to interpret  the severity of a stroke. 
Physicians and  also trained health care professionals caring for patients 
with strokes can asses  this.NIHSSscore, may underestimate the severity 
of a posterior circulation stroke because most of the variables are related 
to symptoms of anterior circulation territory.Similarly ,it also 
underestimate the right middle cerebral artery stroke severity because of 
language function in left. There are different outcome scales  which 
measure different dimensions of recovery and disability. 
 Modified Rankin Scale (mRS)   for assessement of  functional 
independence. 
 Glasgow Outcome Scale (GOS) assessememt of  general level of 
disability and recovery. 
 Barthel Index (BI) assessesment of ability of  self-care and mobility. 
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NIH STROKE SCALE (NIHSS) SCORE
18
 
1. Level of consciousness 5 points 
2. Best gaze on eye movements 2 points 
3. Field of vision  3 points 
4. Facial movements 3 points 
5. Hemiparesis and hemiplegia in extremities 4 points 
6. Each limb is graded individually (4 points for each limb) 
7. Ataxia in each limb 2 points 
8. Sensation on both sides of the body 2 points 
9. Language (presence of aphasia) 3 points 
10. Dysarthria 2 points 
11. Extinction (formerly ‘neglect’) (2 points) 
Interpretation of NIHSS Score  
 
0 – No stroke  
1-4 – Minor stroke  
5-15 – Moderate stroke  
16-20 – Moderate to severe stroke  
21-41 – Severe stroke 
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MODIFIED RANKIN SCALE
19
 
It is the scoring system used for assessing the functional outcome 
after stroke. 
0- patients don’t have any symptoms  
1- Inspite of symptoms patients don’t have significant abnrormality;  they 
can able to do usual daily activities.  
2- patient have mild disability; not able to carry out all activities which 
could be done previously, but able to take care of them  without 
assistance  
3- patient have  moderate disability; need some help, but can walk without 
assistance  
4- Moderate to severe  disability; can’t walk without assistance and need 
help even for self body care. 
5- Severe disability;  patient will be bedridden, and need  constant nursing 
care  
6- Dead 
Total score: 0 to 6 
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OXIDATIVE STRESS 
Oxidative stress results from imbalance between the generation  of 
reactive oxygen species and the  antioxidant defense
20
. 
Increased ROS production through the entire  course of acute 
ischemic stroke especially  in the initial phase can induce the functional 
and structural damage of neuronal cells,  playing  an important role in the 
pathophysiology of brain injury
21
 . 
Low antioxidant activity in the plasma is associated with high 
neurological dysfunction   in acute stroke. 
Oxidative stress and acute ischemic stroke  
High metabolic activity and oxygen consumption which results in  
the  production  of  high levels of  ROS, along with relatively low levels 
of endogenous antioxidant enzymes, mainly catalase  make the neurons   
vulnerable to oxidative stress  .  
ROS reacts with lipids in brain  to  generate peroxyl radicals 
resulting in neuron membrane lipid oxidation . The combination of all 
these  results in   the increased vulnerability of   CNS  to oxidative 
damage. 
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A  decrease in mitochondria redox potential resulting in ROS 
production from the ETC, mainly at  cytochrome III   becomes the chief  
source of free radical generation  during  ischemia
23-25
.  
Excitotoxicity  after ischemia, results in excess cytosolic free  
Ca2+.  This leads to overloading of  the mitochondrial proton circuit, 
resulting in failure of oxidation along  with increased ROS production . 
Increased  ROS formation in mitochondria leads to the impairment 
of the ETC, resulting in decreased ATP production, altered calcium 
homeostasis ,increased formation of free radicals, and mitochondrial 
dysfunction 
22
.  
In the animal study, transient MCA occlusion results in  ROS 
production and mitochondrial dysfunction . Over-expression of 
mitochondrial Hsp70/Hsp75 or antioxidant treatment,   resulting in  
decrease  ROS concentration attenuates mitochondrial dysfunction. 
Excitotoxic pathways  other than mitochondrial dysfunction are 
also important in inducing oxidative stress. It has been proposed  that   
the primary source of superoxide synthesis  following neuronal NMDAR 
activation  is NADPH oxidase,which  are transmembrane proteins 
involving in the    transport  of electrons across biological membranes. 
Usually, oxygen is the electron acceptor and O2−. is the product of the 
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electron transfer reaction . Thus the  function of NOX enzymes is the  
production of ROS. 
During the acute phase of stroke, nNOS gets activated as a result of 
high influx of Ca2+ through NMDA receptors resulting in the  increased  
production of NO . Neuronal NO synthase (nNOS), enzyme  is  tethered 
to the NMDA receptor complex by a protein called  postsynaptic density 
protein-95 (PSD95) .  
During stroke, there  is dramatic increase in nitric oxide production 
in the brain because of the increased activity of   neuronal and inducible 
isoforms of NO synthases .  
Peroxynitrite (ONOO−)  and OH- are formed as a result of 
combination of NO  with H2O2 and O2-  which strongly contributes to 
brain damage  during ischemia. 
 After ischemia ,NO-induced ONOO−causes mitochondrial 
dysfunction and subsequent  increased production  of  free radicals 
leading to  dysfunction of cellular membranes resulting in necrosis.  
The ROS formed in the electron transport chain can  react readily 
with nitric oxide to form  highly reactive peroxynitrite, resulting in the  
damage of  lipids, proteins and DNA 
24-25
. 
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  It is considered that the mitochondrial Ca2+ overload, with 
generation of free radicals, and depression of energy metabolism are most 
important  in the pathogenesis of ischemic brain damage , whereas the 
role of NO is also equally important.  
In a study, after the occlusion of middle cerebral artery, the nitric 
oxide  concentration in that ischemic area increased to micromolar levels. 
The gush in NO levels could  be inhibited by glutamate receptor 
antagonists. It is suggested in  the  study that ,  increased nitric oxide  
metabolite in CSF was associated with greater brain injury and early 
deterioration of neurological function. 
The H2O2 formed from O2− gets converted  to hydroxyl radical 
(OH-)  by the Haber-Weissreaction  which is favoured by iron ions in 
Fenton reaction  or in to water by oxidation of the small tripeptide 
glutathione (GSH) by means of a  reaction which is catalyzed by the  
glutathioneperoxidase (GPX) or mutated to water and oxygen by catalase 
enzyme 
28
.More GSH is produced by the  reduction of the oxidized 
glutathione (GSSG) by a reaction catalyzed by  the enzyme glutathione 
reductase .GSH  converts moreH2O2 to H2O .  Superoxide, causes  
greatest oxidative  damage because of its   participation in peroxinitrite 
(ONOO−) formation28. 
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Oxidative/nitrosative stress can lead to the  damage of  different 
cellular components  by  oxidation of membrane lipids , cell proteins  and 
DNA and also  initiates cascade reactions, resulting in  mitochondrial 
dysfunction and caspases activation and also the activation of signal 
transduction pathways , finally leading to neuronal death. . 
Result from various studies concluded  that oxidative stress plays 
an important role in pathogenesis of ischemic stroke.  
Mosher Muhammad Hussein Kossi et al concluded that oxidative 
stress is an important event in thrombotic stroke and may have 
unfavorable effect in stroke outcome
32
.  
Ayaka Ozkul et al 2007 proposed  the harmful effects of oxidative 
stress  in the  outcome of acute ischemic stroke
31
. 
Jaspreet Kaur et al 2011concluded   that oxidative stress 
contributes to the pathogenesis of acute ischemic stroke and TIA and also 
the imbalance between the oxidant and antioxidant may contribute to the 
severity of stroke
46
. 
Nai-Wen Tsai et al, 2014 concluded  that large-vessel disease have 
higher oxidative stress but less antioxidant defense than small-vessel 
disease
33
. 
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BILIRUBIN AS MARKER OF OXIDATIVE STRESS 
Kazuhiro Utani 2001 et al proposed bilirubin metabolites in urine 
may act as a marker of oxidative stress in septic patients
30
. 
Mehmet Davutoglu et al 2008 concluded that bilirubin had 
significant positive correlation with MDA and NO and  negative 
correlation with anti-oxidant enzyme activities
31
. 
Kenji Dohi 2003 proposed bilirubin levels   serve as an useful 
marker of oxidative stress in patients with hemorrhagic stroke
43
. 
Nesrine salah el din abdul hamim et al (Cairo university  2001) 
concluded that bilirubin level increases as a response to oxidative stress 
and contributes to plasma antioxidant property
34
. 
ANTIOXIDANT ROLE OF  BILIRUBIN  
Various studies  found that different   forms of bilirubin are 
powerful antioxidants: Unconjugated ,conjugated, free and albumin-
bound bilirubin were all found  to be effective scavengers of peroxyl 
radicals .They are able to protect  LDL against peroxidation 
57
.  
Under physiological conditions, bilirubin may acts as a potent 
lipid chain-breaking antioxidant so that increased concentrations of 
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plasma bilirubin may reduce the formation of atheromatous plaque by the 
prevention of formation of oxidized LDL. 
Various animal and human studies have concluded that bilirubin is 
a physiological antioxidant. 
Yamaguchi and co-workers identified biotripyrrins (oxidative 
metabolites of bilirubin) in the urine of healthy humans and ascorbic acid 
depleted rats treated with endotoxin
35
.  
In the same study on feeding a documented physiological 
antioxidant , ascorbic acid, secretion of bilirubin metabolites was reduced 
and  also  there was suppression of the endotoxin-stimulated  
concentration of HO mRNA in liver.  
In another animal study  , ischemia and reperfusion of rat liver 
resulted in induction of  HO-1and  production of biotripyrrins . And there 
was attenuation of both HO induction and biotripyrrin production on 
feeding with ascorbic acid in this model. 
These results denote that bilirubin serves as a strong physiological 
antioxidant in ischemia-reperfusion in vivo and protects against oxidative 
stress. 
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In an experimental study observed in pig hearts cardiac ischemia 
followed by reperfusion was associated with accentuated expression of 
HO-1mRNA and increased reactive vascular HO-1.  
Dennery at al experiments using Gunn rats proposed the 
antioxidant role of bilirubin
47
. 
Another study of vascular balloon injury resulting in  oxidative 
stress and intimal cell proliferation in rat carotid artery showed the 
protective role of bilirubin as an antioxidant. 
And this study suggested that, increased  HO activity and high  
bilirubin serve a protective role  against injury-mediated proliferation of 
intimal cell . 
Various human studies have led to similar conclusions that 
bilirubin play a role as an antioxidant. 
For example, oxidative stress results in   depletion of endogenous 
antioxidants like  bilirubin and increased  production of lipid 
hydroperoxides .  
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Infants with disorders of   oxygen radical mediated injury, such as 
retinopathy of prematurity, intraventricular hemorrhage, 
bronchopulmonary dysplasia, and necrotizing enterocolitis, shows   lower 
circulating bilirubin comparing with  healthy controls .  
Similarly, a direct correlation was found between antioxidant 
status and serum bilirubin concentrations in premature neonates. 
 
BILIRUBIN AND INFLAMMATION 
Role of bilirubin in inflammatory processes and immune reactions 
has also been documented. Nakagami et al. found that both bilirubin and 
biliverdin inhibit complement-mediated reactions and the administration 
of  biliverdin inhibits Forssman anaphylaxis reaction in guinea pigs.   
These findings suggest the protective role of  bile pigments by its 
anticomplement activity.  
The correlation between inflammatory processes and bilirubin is 
supported by evidence that augmented activity of heme oxygenase 
58
resulting in faster recovery of inflammation whereas attenuated activity 
of this enzyme resulting in inflammatory response augmentation.  
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Bilirubin exerts its anti-inflammatory actions by the following 
mechanisms:                                                    
 Decreasing  vascular endothelial proliferation by inhibition of NFkB 
 Inhibits oxidant-mediated activation of leukocytes 
 Anticomplement  activity 
 Inhibition of  leukocyte migration via suppression of VCAM60. 
BILIRUBIN AND  ATHEROSCLEROSIS  
Bilirubin  offers protection against oxidation of  lipoproteins and 
lipids and thereby  reducing the formation of atheroma plaque
38,39
.                                                       
So patients with low bilirubin concentrations may have augmented 
atherogenic plaque formation as a result of increase in lipids and 
lipoproteins oxidation
59
. 
Bilirubin – Heme oxygenase activity  
  Increased HO activity may account for the antiatherogenic  
property of  bilirubin. This is  documented by  increased heme oxygenase 
activity resulting in increased formation of CO, iron, and biliverdin and 
the pathophysiologyof atherosclerosis could be affected by changes in 
any one of these three metabolites. 
For example, HO-1reduces the heme concentration thereby 
preventing heme mediated cell injury. 
In addition,hemoglobin  can act as a scavenger of nitric oxide  that 
affects  NO mediated vasodilatation. 
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FIGURE 6: ILLUSTRATING ROLE OF HEME OXYGENASE IN 
STENOSIS AND NEOINTIMA FORMATION 
 
 
(A)Normal  
 (B) Vascular smooth muscle proliferation  by low concentration of HO-1 
which eventually results in stenosis.  
 (C) Increased  HO-1, by  inhibiting  vascular smooth muscle 
proliferation inhibits neointmal formation. 
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SMOKING AND SERUM BILIRUBIN 
Smoking induces oxidation of lipids due to exposure to LDL. It 
also increases the uptake of modified LDL by macrophages. It has 
already been established that smoking   lowers serum bilirubin 
concentration in males.  
 
HYPERTENSION AND SERUM BILIRUBIN 
Ho Jun Chin et al 2009 concluded, that  increase in bilirubin level 
but within the physiological range had a negative correlation  with  
incidence of hypertension
49
. This  effect of bilirubin was more evident in 
non-smokers and females. 
 
PERIPHERAL VASCULAR DISEASE AND SERUM BILIRUBIN 
The NHANES study concluded  that higher the serum total 
bilirubin level lower the incidence of peripheral arterial disease.Whereas  
patients with low serum bilirubin levels had increased carotid intima-
media thickness and also  abnormal flow-mediated dilation which are 
useful in  predicting cardiovascular disease in normal individuals.   
All these findings gives the conclusion of increased bilirubin levels 
decrease the risk of acquiring cardiovascular disease in normal subjects. 
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CORONARY ARTERY DISEASE AND SERUM BILIRUBIN 
Multiple studies showed inverse relationship between bilirubin 
concentration and incidence of coronary artery disease
38-41
.   In   the 
Framingham offspring study, it had been found that higher  bilirubin 
levels were associated with  decreased risk of  acquiring cardiovascular 
disease in men  
LauraJ.Horsfall,  et al concluded   that lower bilirubin  is a risk 
factor for developing CAD and mortality. 
RHEUMATOLOGICAL DISEASES AND SERUM BILIRUBIN 
In various studies,inverse relationship   was found between serum  
bilirubin levels and some rheumatological disorders. 
 Wegener granulomatosis  
 Systemic lupus erythematosus 
 Rheumatoid arthritis  
 There is an  inverse association between  SLE and serum bilirubin 
levels. The prognosis of  SLE patients is related to the efficiency of 
antioxidant defense systems.  But the low serum bilirubin levels may be  
caused by the consumption of bilirubin during  the pathogenesis of   
oxidative stress in SLE .This concept  might apply for Wegener 
granulomatosis  and Rheumatoid arthritis  , where the same  results have 
been found. 
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DEPRESSION AND SERUM BILIRUBIN 
Wai Kwong Tang suggested that the bilirubin level is a novel, 
important biological marker for the risk of   developing depression in  
ischemic stroke patients
42
.  
On univariate analysis  it was found that more severe stroke was 
associated with higher bilirubin, reflecting the intensity of  oxidative 
stress in the early phase.  Thus severe the  stroke ,greater the risk of  post 
stroke depression.  
  In the study the association found  between the  bilirubin level and 
post stroke depression was independent of severity of stroke.So there 
must be some other possible mechanism for  the association between 
these two.                                      
Among the stroke patients high levels of psychological stress  was 
noted.  There are evidence that urine bilirubin metabolites correlates 
positively with psychological stress.   
Thus , like high  cortisol,  high bilirubin level may denotes a higher 
level of perceived stress, resulting in increased risk of depression. 
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BILIRUBIN IN NEONATE 
Transient increase in unconjugated  bilirubin commonly occurs in 
newborns, which is called as as “physiologic jaundice,” .It usually  
further resolves without any consequences. Physiologic jaundice  offers 
protection against oxidative stress causing damage to neonatal tissue. 
But  the unconjugated bilirubin levels may increase above the 
physiologic range from additional sources of hemolysis. Trauma during 
birth, G6PD deficiency and ABO or Rh blood incompatibilities are the 
additional sources of hemolysis. 
This pathologic increase in bilirubin can be neurotoxic resulting in 
neonatal bilirubin encephalopathy( kernicterus ). Basal ganglia and other  
brain stem nuclei  are affected by acute bilirubin encephalopathy . 
Thus bilirubin has been found to confer both neuroprotective 
antioxidant characteristics as well as neurotoxic properties . A complete 
knowledge of the interactions between bilirubin and central nervous 
system is needed  since it may have profound clinical implications in the 
treatment modalities used in the critical care setting.  
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BILlRUBIN AND NEUROPROTECTION  
Unconjugated bilirubin cant crosses intact blood brain barrier, 
which prevents its  accumulation  in the CNS, since most of the 
unconjugated  bilirubin found in plasma  is bound to albumin   . When 
bilirubin acts  as an antioxidant,   biliverdin is formed by the oxidation  of 
bilirubin, but  again bilirubin  is formed by the action of  biliverdin 
reductase.  
This  explains  even  in low  concentrations in neuronal cell 
cultures bilirubin exerts its powerful antioxidant property.  HO-
2constitutes the  major form of heme oxygenase  in the central nervous 
system, whereas HO-1 is found  in specific cell types in the brain such as 
microglia and macrophages.  
Recently in  an animal study  done in rats ,  after the occlusion of 
middle cerebral artery, propofol post-treatment there was evidence of   
attenuation of ischemic damage  partly by  up regulation of  HO-1. 
Similarly,  in an experimental study done in  mouse following  
cerebral ischemia showed  greater  damage of neurons in HO-2 knockout 
mice compared to normal  counterparts,  supporting the concept of 
neuroprotective role of bilirubin.  
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BILIRUBIN AND NEUROTOXICITY  
Bilirubin not only serves   protective role in neurological diseases ,  
there are evidence stating the role of bilirubin in the progression of 
neurological dysfunction in various  pathological conditions. 
In most of these pathological states,there is increase in bilirubin 
levels above physiologic range,so that the toxic effects of bilirubin 
exceed the protective role.   This effect will, results in  damage to the  
central nervous system.  
The neurotoxic effects of bilirubin starts above a certain 
micromolar concentrations, and when that level is reached  it will 
aggregate and adhere to cellular membranes,  resulting in the disruption  
normal function.   
Drugs can compete with bilirubin for albumin-binding sites 
,resulting in increase of plasma bilirubin levels. 
 For example, bilirubin can be displaced from albumin by fatty acid 
components which leads to amplification of  bilirubin related  
neurotoxicity in susceptible patients. 
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NEUROTOXICITY OF INDIRECT  BILIRUBIN  
 
But Maria Alexandra Brito  et al observed the role of  
unconjugated bilirubin in promoting lipid peroxidation, ROS formation  
and protein oxidation in synaptosomal membrane systems
37
. 
Similarly,in another study it has been proposed that the 
pathogenesis of encephalopathy by hyperbilirubinemia is due to action of 
unconjugated bilirubin  by induction of oxidative stress
48
. 
  Cristina Bellarosa 2011   proposed that increased unconjugated 
bilirubin (UCB) can result  in bilirubin encephalopathy.Oxidative and 
Endoplamic Reticulum  stress are suggested to be involved bilirubin 
induced neurotoxicity
36
. 
NEUROTOXICITY OF BILIRUBIN AND HEMORRHAGIC 
STROKE 
When a weakened blood vessel ruptures hemorrhagic stroke 
occurs, which results in bleeding into the brain substance and neuronal 
injury subsequently. There are  additional complications  in hemorrhagic 
57 
 
stroke patients resulting in secondary damage which occurs  days after 
the initial event  such as cerebral ischemia  and vasospasm. 
HO-1  in the brain is induced by the blood presence locally 
resulting in increased  production of unconjugated bilirubin . 
There are clinical evidence which supports the concept , that the 
environment immediately  around the hematoma is highly contributing to 
oxidative reactions, augmenting the conversion of bilirubin into bilirubin 
oxidation products.  
BOXes(bilirubin oxidation products) in CSF have temporal 
relationship with the   time  of onset of cerebral vasospasm, and proved to 
be vasoactive.  
These findings collectively gives a conclusion that BOXes   can 
either cause or contribute to vasospasm and  also the resulting delayed 
neurologic dysfunction following hemorrhagic stroke
43
.  
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ISCHEMIC STROKE AND SERUM BILIRUBIN 
In 1971 herishanu et al in a study found that hyperbilirubinemia 
was prevalent in  patients with acute ischemic stroke during the first 48 
hours after the onset of stroke symptoms., whereas liver enzymes and 
other values   were normal in the same patients,but  they couldn’t 
substantiate this discrepancy. 
There are studies supporting the evidence of protective role of 
bilirubin  in  the incidence of cardiovascular and cerebrovascular 
diseases
51-52,44
.  
But ,it has been proposed by various studies  that during the acute 
phase of ischemic stroke bilirubin levels  get elevated   . 
And patients with higher level of bilirubin had severe disease and 
worse outcomes. 
Bilirubin causes brain damage by 
 Mitochondrial enzymes inhibition,  
 Disrupt  of DNA synthesis, and 
 Attenuation of  protein production. 
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Nicholas V Mendez1 
45
et al 2013 explained about the role of 
bilirubin in ischemic stroke as follows, 
In Ischemic stroke when blood flow to a part of  brain is obstructed  
either by thrombus or embolus ,there will be hypoxic ischemic state, 
which produces downstream hypoxic-ischemic conditions resulting in 
increased oxidative stress. 
In these conditions, HO-1 induction takes place resulting in 
amplification of  bilirubin formation. It has been proposed that the serum 
bilirubin level is a biomarker of the degree of ischemic damage following 
stroke. 
These findings suggest that the   bilirubin may be used as an early  
prognostic marker of stroke severity and outcome  during the 
management of patients having ischemic stroke.  
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MATERIALS AND METHODS 
 
SETTING: 
Patients admitted in  Kilpauk Medical College and Hospital, Chennai.  
COLLABORATING DEPARTMENTS  : 
Neurology, Radiology, Biochemistry 
PERIOD OF STUDY: 
April  2014 to September 2014 
STUDY DESIGN: 
Case control Study (Ischemic stroke patients as cases and non stroke 
persons as control group) 
STUDY POPULATION: 
All patients presenting with new onset neurological deficit 
following ischemic stroke within 48 hours of onset of stroke  admitted in 
the medical wards were included in the study.  
An equal number of age, sex and comorbid conditions[Diabetes 
Mellitus, Systemic Hypertension] matched persons not having stroke 
attending OPD were included in the study as control group 
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DEFINITIONS FOLLOWED IN THIS STUDY 
STROKE 
In this study,Stroke was defined as rapid onset of focal  
neurological deficit lasting  for more than twenty four hours or resulting 
in death with no cause apparently other than vascular etiology.      
HYPERTENSION 
Hypertension was diagnosed when it was  documented in medical 
records or  who were on regular intake of drugs for  hypertension.  
DIABETES 
Diabetes was diagnosed with past medical records or when patients 
were on oral anti-diabetic drug or insulin 
ALCOHOLISM 
Patient was defined as alcoholic when there was a history of 
alcohol consumption in past 5 years. 
SMOKER 
Patients was diagnosed as smoker when there was smoking history 
in past 5 years. 
NIHSS SCORE: NIHSS scoring was done on the basis of the clinical 
parameters. In this study, patients with score ≥10 were considered as 
having severe stroke 
MRS SCORE: MRS score of <3were considered as Good Outcome and 
scores of ≥3were considered as Poor outcome. 
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INCLUSION CRITERIA 
All patients presenting with new onset neurological deficit 
following ischemic stroke admitted within 48 hours of onset of stroke.  
EXCLUSION CRITERIA 
Patients with  
o H/O alcoholism 
o Known liver disease  
o Known Chronic Kidney disease 
o Known Coronary artery disease 
o Known Malignancy 
o Known Connective Tissue Disorders 
o Hemodynamic instability – BP<90/60mmHg 
o Hepatotoxic drug intake in past 30 days  
o Infection identified through history and clinical examination 
o Haemorrhagic Stroke Patients (ICH,SDH,EDH ) - with the aid of 
CT/MRI scan  
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STUDY METHODS 
This study is to compare the serum total bilirubin levels between 
acute   ischemic stroke patients  and non stroke subjects and its 
significance among them. And also to identify whether there is  any 
association between stroke severity and prognosis with serum  total 
bilirubin level.  
Patients/relatives were explained about the study. Patients were 
included in the study after obtaining written informed consent.  
Fifty patients who had acute ischemic stroke   and fifty controls 
were included for study. Patients who got admitted within 48 hours of 
stroke onset only were taken under  study. Then complete relevant 
medical history, neurological examination, relevant blood  investigations 
and CT/MRI scan were done and all data were recorded in a standardized 
proforma.  
CT/MRI scan was done for the exclusion of  hemorrhagic stroke.  
Blood sample for  Serum total and direct bilirubin and  other baseline 
investigations was taken as soon as patient got admitted . National 
Institute of Health Stroke Scale (NIHSS) scoring was assessed  at the 
time of admission and these patients were grouped according to score of 
<10 and ≥10  
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These patients were treated according to standard  protocols. None 
of the patients were thrombolysed.. Modified Rankin Scale was assesed 
to know the functional recovery of the patient after 7 days  either in ward 
or in   review opd if got discharged. 
Similarly subjects in control group were studied by relevant 
medical history,and clinical examnation  and relevant blood 
investigations. 
All the subjects in control group were selected   in respect to  
age(group match),gender,co-morbid conditions  ( diabetes and  
hypertension ) matched with cases. 
BIOCHEMICAL ANALYSIS  
Blood samples were taken as soon as the patient admitted in case 
group and in control group randomly.  Serum bilirubin was measured by 
spectrophotometry method in the laboratory  using   Jendrassik-Grof 
allied methods. 
 
 
 
 
65 
 
DATA ANALYSIS  
Continuous variables like age and bilirubin level were expressed as 
mean (Standard Deviation). Association between ischemic stroke and 
total bilirubin level was tested by comparing serum bilirubin levels in 
ischemic stroke patients with that of controls using unpaired 
(Independent) t test. A P value of <0.05 was considered as statistically 
significant.  
Severity of stroke on admission was assessed by NIHSS severity 
scale (NIHSS> 10 was considered as Severe stroke) and the prognosis of 
stroke on 7
th
 day of stroke was be assessed by Modified Rankin 
functional outcome Scale (MRS >3was considered as poor prognosis). 
Total bilirubin levels were divided in to three groups, (Group 1:  < 
0.6mg/dl, Group 2: 0.7 to 0.9mg/dl, Group 3: >1.0 mg/dl). Severity of 
stroke, prognosis of stroke was expressed as percentages and its 
correlation with three groups of bilirubin was tested by Chi Square 
analysis. A P value of <0.05 was considered as statistically significant. 
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RESULTS AND ANALYSIS 
 
TABLE 7: AGE DISTRIBUTION IN STUDY GROUP 
 
 
 
Parameter 
Cases Control P value 
 
 
 
 
Mean age in 
Years (SD) 
59.7 (11.97) 58.28 (10.1) 0.523 
 
 
There is no statistically significant difference in respect to age among 
case and control group. 
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TABLE 8: AGE DISTRIBUTION IN STUDY GROUP 
 
 
AGE (IN YEARS) 
 
 
NO.OF CASES(n) 
 
 
NO.OF CASES(%) 
≤ 50 13 26% 
> 50 37 74% 
TOTAL 50 100% 
 
FIGURE 7: DISTRIBUTION OF CASES IN AGE GROUP 
 
 
Out of 50 cases, 26%, 13 cases were in the age group ≤50 years and 74%, 
37 were in the age group >50 years. 
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TABLE 9: GENDER DISTRIBUTION IN STUDY GROUP 
Gender Cases (n=50) Controls (n=50) 
Male 38 (76%) 38 (76%) 
Female 12 (24%) 12 (24%) 
Total 50 (100%) 50 (100%) 
 
FIGURE 8: DISTRIBUTION OF CASES IN GENDER GROUP 
  
 
In the study, among the 50 cases ,76% ,38 cases were males and 24 %, 12 
cases were females ,as the controls  were sex matched equal numbers 
found in control group. 
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TABLE 10: DISTRIBUTION OF TOBACCO SMOKING IN STUDY 
GROUP 
 
Gender Cases(n=50) Controls(n=50 ) 
Smoker 14 (28%) 14 (28%) 
Non smoker 36 (72%) 36 (72%) 
Total 50 (100%) 50 (100%) 
 
FIGURE 9: DISTRIBUTION OF TOBACCO SMOKING IN STUDY 
GROUP 
 
 
In the study population, both among the case and control group 28%,14 
were smokers and 72%,36 were non smokers.   
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TABLE 11: BODY MASS INDEX OF CASE AND CONTROL GROUP 
BMI CASE, n (%) CONTROL, n (%) 
<18.5 0 5 (10) 
18.5-22.9 27 (54) 26 (52) 
23-24.9 12 (24) 11 (22) 
≥25 11 (22) 8 (16) 
Total 50 (100) 50 (100) 
 
 There is no major difference in BMI among case and control. 
Majority of the both cases and control were in the range of 18.5 to 22.9 
BMI. 
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TABLE 12: DISTRIBUTION OF DIABETES AMONG CASES & 
CONTROL 
PARAMETERS CASE CONTROL 
Diabetic 14(28%) 14(28%) 
Non-Diabetic 36(72%) 36(72%) 
 
 
FIGURE 10: DISTRIBUTION OF DIABETES AMONG CASES & 
CONTROL 
 
 
 In the study population, 28%, 14 were 
diabetics and 72 %, 36 were non diabetics in both case and control group 
as controls were matched for diabetes. 
 
 
 
Diabetic
, 14 
Non-
Diabetic
, 36 
Cases 
Diabetic
, 14 
Non-
Diabetic
, 36 
Controls 
72 
 
 
FIGURE 11: DISTRIBUTION OF SYSTOLIC BLOOD PRESSURE IN 
STUDY GROUP. 
 
 
 
 
Box plot of systolic blood pressure shows that median systolic 
blood pressure was 120 and 130 among controls and cases respectively.  
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FIGURE 12: DISTRIBUTION OF DIASTOLIC BLOOD PRESSURE IN 
STUDY GROUP. 
 
 
 
 
 
 
Box plot of diastolic blood pressure shows that median diastolic 
blood pressure was 80 and 86 among controls and cases respectively.  
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FIGURE 13: TOTAL CHOLESTEROL AMONG CASE AND CONTROL 
GROUP 
 
The total cholesterol among two groups doesn’t show statistical 
difference. 
FIGURE 14: HDL AMONG CASE AND CONTROL GROUP 
 
The HDL among two groups doesn’t show statistical difference. 
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FIGURE 15: LDL AMONG CASE AND CONTROL GROUP 
 
 
 
The LDL among two groups doesn’t show statistical difference. 
FIGURE 16: TG AMONG CASE AND CONTROL GROUP 
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TABLE 13: LIPID PROFILE OF CASE AND CONTROL GROUP 
 
Parameter 
 
 
CASE 
 
CONTROL 
 
p value 
Total 
Cholesterol 
162.72 (35.48) 163.12 (29.61) 0.951 
HDL 36.94 (8.44) 39 (6.53) 0.175 
LDL 
 
100.3 (27.18) 101.28 (20.76) 0.84 
TG 114.04 (43.81) 99.32 (34.19) 0.064 
 
 
The lipid profile parameter does not imply any significant 
differences in total cholesterol, HDL, LDL, TG among the case and 
control group. 
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FIGURE 17: LIPID PROFILE OF CASE AND CONTROL GROUP 
 
 
There were no significant differences in total cholesterol, HDL, 
LDL, TG among the case and control group. 
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TABLE 14: LIVER ENZYMES IN CASE AND CONTROL GROUP 
Liver Enzymes Case Control p value 
 
AST 
 
14.82 (7.6) 
 
16.76 (11.2) 
 
0.314 
 
ALT 
 
22.82 (11.18) 
 
23.92  
(11.6) 
 
0.63 
 
 The difference in the liver enzyme Aspartate Transaminase(AST), 
Alanine Transaminase(ALT) among the case and control group is not 
statistically significant. 
FIGURE 18: LIVER ENZYMES IN CASE AND CONTROL GROUP 
 
 
 
 
  
0 
5 
10 
15 
20 
25 
AST ALT 
14.82 
22.82 
16.76 
23.92 
IU/L 
Liver Enzymes 
Case  
Control  
79 
 
 
TABLE 15: MEAN (SD) TOTAL BILIRUBIN IN CASE AND CONTROL 
GROUP 
Parameter Cases (n=50) Controls (n=50) p value 
Mean Total 
Bilirubin (SD) 
0.976 (0.328) 0.64 (0.249) <0.001 
 
FIGURE 19: MEAN (SD) TOTAL BILIRUBIN IN CASE AND CONTROL 
GROUP 
 
 The mean total bilirubin in cases was 0.976, whereas in control 
group it was 0.64. Thus there is positive   correlation between total 
bilirubin and acute ischemic stroke and it is statistically significant. 
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TABLE  16: MEAN (SD) DIRECT BILIRUBIN IN CASE AND 
CONTROL GROUP 
Parameter Cases (n=50) Controls (n=50) p value 
Mean Direct 
Bilirubin (SD) 
0.262 (0.199) 0.237 (0.123) 0.452 
 
FIGURE 20: MEAN (SD) DIRECT BILIRUBIN IN CASE AND 
CONTROL GROUP 
 
 The mean direct bilirubin in cases was 0.262 and in control group 
is 0.237, so there is no correlation between direct bilirubin and acute 
ischemic stroke  
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TABLE 17: MEAN (SD) INDIRECT BILIRUBIN IN CASE AND 
CONTROL GROUP 
Parameter Cases (n=50) Controls (n=50) p value 
Mean Indirect 
Bilirubin (SD) 
0.714 (0.286) 0.403 (0.186) <0.001 
 
FIGURE 21: MEAN (SD) INDIRECT BILIRUBIN IN CASE AND 
CONTROL GROUP 
 
 The mean indirect bilirubin in cases was 0.714 and in control group 
was 0.403,so there is a  positive correlation between indirect bilirubin and  
acute ischemic stroke and it is statistically significant. 
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TABLE 18: TOTAL BILIRUBIN IN CASE AND CONTROL GROUP 
Total Bilirubin Case, n (%) Control, n (%) 
≤0.6 6 (12%) 26 (52%) 
0.7-0.9 25 (50%) 18 (36%) 
≥1.0 19 (38%) 6 (12%) 
Total 50 (100%) 50 (100%) 
P value: <0.001 
 In the study,out of 50 cases 12%,6 cases had total bilirubin in the 
range ≤ 0.6,50%,25 cases had  total bilirubin in the range of 0.7 -
0.9,38%,19 cases had total bilirubin in the range ≥1.0. 
  Among the control group,52%,26 subjects  had  total bilirubin in 
the range ≤0.6, 36%,18 subjects had total bilirubin in the range of 0.7 -
0.9, 12%,6 cases had  total bilirubin in the range of ≥1.0. 
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FIGURE 22: TOTAL BILIRUBIN IN CASE AND CONTROL GROUP 
 
 
 Thus 44 cases had total total  bilirubin in the range ≥0.7 and only 6 
cases had  total bilirubin ≤0.6. 
 So the association between the acute ischemic  stroke  and 
admission  total bilirubin is statistically significant comparing with 
control group. 
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FIGURE 23: CATEGORIES ACCORDING TO NIHSS 
 
 
 In the study, out of the 50 cases (36%) 18 cases had NIHSS ≤9 at 
admission and (74%) 32 cases had severe stroke NIHSS ≥10 at 
admission. 
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FIGURE 24: CATEGORIES ACCORDING TO MRS 
 
 
 
 
 
 In the study ,out of the  50 cases (28%) 14 cases had good outcome 
after 7 days of onset of stroke(MRS <3) and(72%)36 cases had poor 
outcome after  7 days of onset of stroke(MRS≥3) 
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TABLE 19: ASSOCIATION OF TOTAL BILIRUBIN WITH NIHSS 
SCORE AMONG CASES 
Total 
Bilirubin 
NIHSS 
≤9 ≥10 Total 
 ≤0.6 6(100%) 0(0%) 6(100%) 
0.7-0.9 10 (40.0%) 15 (60.0%) 25 (100%) 
1.0 and above 2 (10.5%) 17 (89.5%) 19 (100%) 
Total 18 (36%) 32 (64%) 50 (100%) 
P value= 0.0003 
 In the study, among 18 cases (36%) who had (NIHSS ≤9), six 
cases had  total bilirubin in the range of ≤ 0.6, 10 cases had total  bilirubin 
in the range of 0.7-0.9 and only 2 cases had  total bilirubin ≥ 1. 
 Among 32 cases (64%) who had (NIHSS≥10), none of them had  
total bilirubin in the range of ≤ 0.6, 15 cases had total bilirubin in the 
range of 0.7-0.9 and 17 cases had total bilirubin ≥ 1.  
 
 
 
 
 
 
87 
 
FIGURE 25: ASSOCIATION OF TOTAL BILIRUBIN WITH NIHSS 
SCORE AMONG CASES 
 
 
 Thus, 32 cases with severe stroke(NIHSS≥10) had  total bilirubin 
ranging ≥0.7. So, the association between the admission total bilirubin 
level and NIHSS at admission is statistically significant. 
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TABLE 20: ASSOCIATION OF TOTAL BILIRUBIN WITH MRS SCORE 
AMONG CASES 
Total Bilirubin 
MRS 
<3 ≥3 Total 
 ≤0.6 5(80%) 1(20%) 6(100%) 
  0.7-0.9  9 (36%) 16 (64%) 25 (100%) 
 1.0 and above 0(0%) 19 (100%) 19 (100%) 
  Total 14 (28%) 36 (72%) 50 (100%) 
p value: 0.0002 
 In the study, among  the  14 cases (28%) who had good outcome 
after 7 days (MRS<3), 5 cases (80%) had  total bilirubin in the range of 
≤0.6, 9 cases(36%) had total  bilirubin in the range of 0.7 -0.9 and none 
of them had total  bilirubin 1 or above, whereas among the 36 cases(72%) 
who had poor outcome after 7 days(MRS≥3),only 1 case had total 
bilirubin in the range of ≤0.6, 16 cases(64%) had  total bilirubin in the 
range of 0.7 -0.9 and 19 cases (100%) had  total bilirubin ≥  1.  
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FIGURE 26: ASSOCIATION OF TOTAL BILIRUBIN WITH MRS 
SCORE AMONG CASES 
 
 
 
 Thus 35 cases who had poor outcome after 7 days had total 
bilirubin in the range of 0.7 and above at the time of admission. So, the 
association between the admission total bilirubin and stroke outcome 
after 7 days is statistically significant 
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TABLE 21: ASSOCIATION OF MEAN DIRECT BILIRUBIN WITH 
NIHSS SCORE AMONG CASES 
 
NIHSS group Mean direct bilirubin 
(SD) 
P value 
0-9 0.22(0.15)  
0.23 
10 and above 0.29 (0.22) 
 
 The difference in Mean Direct Bilirubin between the two groups is 
not statistically significant. 
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FIGURE 27: ASSOCIATION OF MEAN DIRECT BILIRUBIN WITH 
NIHSS SCORE AMONG CASES 
 
 
 
 The Mean Direct Bilirubin in severe stroke patients (NIHSS>10) is 
0.29 whereas in another group(NIHSS<9) is 0.22 and the difference is not 
statistically significant. 
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TABLE 22: ASSOCIATION OF MEAN DIRECT BILIRUBIN WITH MRS 
SCORE AMONG CASES 
MRS group Mean direct bilirubin 
(SD) 
P value 
<3 0.22(0.14)  
0.37 
≥3 0.28 (0.18) 
 
 The difference in Mean Direct Bilirubin between the two groups is 
not statistically significant. 
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FIGURE 28: ASSOCIATION OF MEAN DIRECT BILIRUBIN WITH 
MRS SCORE AMONG CASES 
 
 
 
 The Mean Direct Bilirubin in poor outcome patients (MRS>3) is 
0.28 whereas in another group (MRS<3) is 0.22 and the difference is not 
statistically significant. 
 
 
 
 
 
0.22 
0.28 
0 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
<3 >=3 
M
ea
n
 D
ir
e
ct
 B
ili
ru
b
in
 
MRS Score 
Mean direct bilirubin 
94 
 
TABLE 23: ASSOCIATION OF MEAN INDIRECT BILIRUBIN WITH 
NIHSS SCORE AMONG CASES 
NIHSS group Mean indirect bilirubin 
(SD) 
P value 
0-9 0.56(0.16) 0.003 
10 and above 0.80 (0.31) 
 
 The difference in Mean Indirect Bilirubin 
between the two groups is statistically significant. 
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FIGURE 29: ASSOCIATION OF MEAN INDIRECT BILIRUBIN WITH 
NIHSS SCORE AMONG CASES 
 
 
 
 The Mean Indirect Bilirubin in severe stroke patients (NIHSS>10) 
is 0.8 whereas in another group (NIHSS<9) is 0.56 and the difference is 
statistically significant. 
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TABLE 24: ASSOCIATION OF MEAN INDIRECT BILIRUBIN WITH 
MRS SCORE AMONG CASES 
 
 
MRS group 
Mean indirect bilirubin 
(SD) 
P value 
<3 0.51(0.16) 
0.001 
≥3 0.79 (0.26) 
 
 The difference in Mean Indirect Bilirubin between the two groups 
is statistically significant. 
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FIGURE 30: ASSOCIATION OF MEAN INDIRECT BILIRUBIN WITH 
MRS SCORE AMONG CASES 
 
 
 
 The Mean Indirect Bilirubin in poor outcome patients (MRS>3) is 
0.79 whereas in another group(MRS<3) is 0.51 and the difference is 
statistically significant. 
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TABLE 25: ASSOCIATION OF NIHSS AND MRS 
 
NIHSS MRS  
<3 ≥3 Total 
≤9 10 (55.6) 8 (44.4) 18 (100) 
≥10 4 (12.5) 28 (87.5) 32 (100) 
Total 14 (28) 36 (72) 50 (100) 
p value= 0.001 
 
 In the study, among 18 cases who had NIHSS ≤9 at admission, 10 
cases (55.6%) had good outcome (MRS <3) after 7 days and 8 cases 
(44.4%) had poor outcome (MRS ≥3) after 7 days.  
 Among 32 cases who had   NIHSS ≥10 at admission, only 4 cases 
(12.5%) had good outcome (MRS <3) and 28 cases (87.5%) had poor 
outcome (MRS ≥3) after 7 days.  
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FIGURE 31: ASSOCIATION OF NIHSS AND MRS 
 
 Thus the association between NIHSS at admission and MRS after 7 
days is statistically significant. 
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DISCUSSION 
Bilirubin once considered to be the toxic waste product, in recent 
days gained importance because of its antioxidant property. 
Various studies proposed about the role of bilirubin in oxidative 
stress mediated diseases like stroke, coronary artery diseases, cancer etc.  
There are studies  which concluded  that greater admission  serum 
bilirubin levels were  associated   with greater stroke severity and  poor  
short term outcome. 
Several studies have proved that the synthesis of bilirubin is 
induced in response to oxidative stress.  
So the high bilirubin level at the admission found in ischemic 
stroke patients may be simply due to oxidative  stress pathway induction 
and bilirubin  may play  no  role in protection against neurological 
damage.     
In this Case control Study (Ischemic stroke patients as cases and 
non stroke persons as control group) conducted in Kilpauk Medical 
College during the period of April 2014 to September 2014, I analysed 50 
patients who had Ischemic stroke were   taken as cases, 50 patients who 
did not have stroke were taken as control group. 
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All the cases and controls were subjected to complete investigation 
and were analyzed for difference in serum total bilirubin levels between 
cases and controls.  
Further analysis was done to find any association exists between 
total bilirubin and stroke severity at admission and prognosis after 7 days. 
In the study, mean total bilirubin was higher in cases than controls 
and the difference is stastically significant (p <0.001) and also the 
indirect bilirubin was also higher in cases significantly but the direct 
bilirubin didn’t showed such results.  
Among the cases, 74 % had severe stroke on admission and 72% 
had poor functional outcome after 7 days. 
Patients with higher total bilirubin level ( i.e in the second and third 
group of  total bilirubin ) at admission had severe stroke(p0.0003) and it 
was positively correlated with significance. 
This is supported by the study conducted by Tian Xu et al , 
concludes that elevated serum total bilirubin positively correlates with 
stroke severity 
Patients with higher total bilirubin level ( i.e in the second and third 
group of  total bilirubin ) at admission had poor outcome and it was 
positively correlated with significance. (p 0.0002) 
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Most of the studies conducted on ischemic stroke and bilirubin   
found statistically significant association between admission bilirubin and 
short term clinical outcome.  
 Arsalan et al found stastically significant  correlation between 
bilirubin and short term outcome. 
In the study, direct bilirubin levels  were not correlated both with 
severity and functional outcome. But this result is not supported by any of 
the previous similar studies. 
Sandra Pineda et al concluded higher admission direct bilirubin is 
associated with greater stroke severity.  
In the study, indirect bilirubin levels were elevated in cases 
significantly(p0.001) and also correlates with stroke severity(p0.003) and 
functional outcome.(p0.001). 
 
In the study the mean AST, ALT between two groups didn’t have 
any stastistically  significant differences. This association has not been 
analysed extensively. 
In the study, there is a positive  correlation between severe stroke 
and poor outcome and it is statistically significant.   
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Above findings support the hypothesis that serum bilirubin might 
act as the endogenous antioxidant, but during the acute phase of stroke it   
acts as the marker of oxidative stress damage.  
Whatever the preventive or destructive function in ischemic stroke, 
bilirubin is elevated in ischemic stroke which is related to stroke severity 
and poor functional outcome and bilirubin can act as the marker of 
oxidative stress.  
So further study in the role  of bilirubin in the pathogenesis of 
ischemic stroke is warranted, as it may have numerous clinical 
implications. 
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LIMITATIONS OF THE STUDY  
But the limitation of the study  are hepatitis virus carriers were not 
excluded  from the study considering the low incidence of carriers who 
didn’t  developed  jaundice at least once in the life time in local 
population and   second is the small study group. 
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CONCLUSION 
In summary ,this study found that serum total  and indirect 
bilirubin levels are higher in acute ischemic stroke patients. Serum total 
and indirect bilirubin levels   were correlated positively and significantly 
with stroke severity NIHSS≥10 and poor   short term functional outcome 
MRS ≥ 3. 
CLINICAL IMPLICATIONS 
Since bilirubin acts as the marker of oxidative stress in stroke 
patients, measures to reduce oxidative stress  in patients with higher 
bilirubin will be taken as therapeutic measure to reduce morbidity and 
mortality.  
And also with this basic investigation, severity and prognosis of 
stroke can be assessed and Ischemic stroke patients with higher bilirubin 
levels can be monitored to avoid complications.  
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ANNEXURES 
 
ABBREVIATION 
 
 
 
 
 
 
 
 
 
 
Accronym Abbreviation Accronym Abbreviation
ACA Anterior Cerebral Artery MDA Malondialdehyde
AIS Acute Ischemic Stroke MI MyocardialInfarction
ALT Alanine Transaminase MRA Magnetic Resonance Angiography
AST Aspartate Transaminase MRI Magnetic Resonance Imaging
BOX Bilirubin Oxidative Metabolites MRS Modified Rankin Scale
B-UGT Bilirubin-UDP Glucouronosyl TransferaseNIHSS National Institure of Health Stroke Scale
CAD Coronary Artery Disease NMDAR NMDA Glutamate Receptor
CADASIL Cerebral autosomal dominant 
arteriopathy with
 subcortical infarcts and 
leukoencephalopathy 
nNOS Neuronal Nitric Oxide Synthase
CNS Central Nervous System NO Nitric Oxide
CO Carbon Monoxide NOX NADPH Oxidase
CSF CerebroSpinal Fluid O2- Super Oxide Anion
CT Computed Tomography OH- Hydroxyl Radical
CTA Computed Tomography Angiography ONOO- Peroxy Nitrite
DB Direct Bilirubin PCA Posterior Cerebral Artery
DIC Disseminated Intravascular Coagulation PET Postitron Emission Tomography
DM Diabetes Mellitus PTT Partial Thromboplastin Time
EDH Extradural Hemorrhage ROS Reactive Oxygen Species
ES Embolic Stroke rt-PA Recombinant Tissue - Plasminogen Activator
ETC Electron Transport Chain SAH Sub Arachnoid Hemorrhage
G6PD Glucose 6 Phosphate Dehydrogenase SDH Subdural Hemorrhage
HDL High Density Lipoprotein SHT Systemic Hypertension
HI Hemorrhagic Infarction SLE Systemic Lupus Erythematosus
HO Hemeoxygenase SPECT Single-photon emission computed tomography
IB Indirect Bilirubin TB Total Bilirubin
ICH Intra Cranial Hemorrhage TC Total Cholesterol
ICT Intra Cranial Tension TG Triglyceride
INR International Normalized Ratio TIA Transient Ischemic Attack
LDL Low Density Lipoprotein TTP Thrombotic Thrombocytopenic Purpura
MCA Middle Cerebral Artery VCAM Vascular Cell Adhesion Molecule
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PROFORMA 
NAME IP NO SL. NO: 
   
 
AGE      :  
SEX      :  
OCCUPATION    :  
ADDRESS     :  
DATE AND TIME OF STROKE :  
DATE AND TIME  OF ADMISSION:            
DATE OF DISCHARGE   : 
            
 CT/MRI BRAIN:INFARCT   : Y/N 
  
LOCATION     : ACA/MCA/PCA [Water Shed,  
 
 /Global/Lacunar/Others ] 
Bilirubin:       
TOTAL 
BILIRUBIN 
 
DIRECT  
INDIRECT  
 
 
NIHSS SCORE AT THE TIME OF ADMISSION (Severity 
Assessment): 
 
MRS AT 7
TH
 DAY OF STROKE(Prognosis Assessment):  
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MASTER CHART: CASES 
S.No NAME AGE SEX SMOKING BMI DM SHT BP 
LIPID PROFILE LIVER ENZYMES BILIRUBIN 
TERRITORY NIHSS MRS 
TC HDL LDL TG AST ALT TB DB IB 
1 KATHARAVAYAN 60 M - 23.5  - 130/80 213 34 130 265 38 50 0.9 0.5 0.4 MCA 5 1 
2 ARUMUGAM 52 M - 21.5  - 120/80 122 35 70 54 16 24 1.1 0.3 0.8 MCA 9 3 
3 ASAITHAMBI 45 M  21.8 - - 120/70 97 24 65 92 12 16 0.9 0.2 0.7 MCA 8 3 
4 RADHA 73 F - 23.8 - - 130/70 159 38 97 100 14 28 1.4 0.8 0.6 MCA 28 6 
5 MANI 48 M - 20.3 - - 140/96 150 50 76 72 18 22 0.5 0.2 0.3 MCA 7 1 
6 PADMAVATHI 70 F - 23.4   150/96 154 36 82 106 36 50 1.6 0.2 1.4 MCA 30 5 
7 SUDHAKAR 33 M - 29.8  - 140/86 216 30 146 218 10 14 0.8 0.1 0.7 MCA 25 4 
8 RAVI 55 M - 21.5 -  160/90 220 56 130 150 17 26 0.6 0.1 0.5 ACA 9 2 
9 KRISHNAMOORTHY 60 M  30.4   160/86 226 35 164 132 12 12 1.5 0.3 1.2 VBA 29 4 
10 JAYAKUMAR 48 M - 22 -  140/96 196 48 126 146 16 8 0.9 0.2 0.7 MCA 7 2 
11 SEKAR 45 M  23.2 -  150/90 156 36 98 160 14 18 0.9 0.1 0.8 MCA 12 3 
12 THIRUMAL 73 M - 19.5 -  160/100 140 30 94 86 16 28 1.4 0.2 1.2 MCA 26 4 
13 KRISHNAMOORTHY 65 M - 18.6 -  140/90 186 40 128 112 9 16 0.8 0.1 0.7 MCA 11 5 
14 SEKAR 55 M  26.5 - - 130/86 216 30 146 148 30 42 0.8 0.2 0.6 MCA 10 2 
15 DURAISAMY 72 M - 21 - - 150/100 150 45 86 72 9 16 0.8 0.1 0.7 MCA 8 3 
16 SATHYA 37 M  22 - - 160/90 194 34 124 74 12 15 1.5 0.8 0.7 MCA 28 4 
17 SIVALINGAM 66 M - 28.5 - - 120/76 176 40 112 124 16 20 1.0 0.5 0.5 MCA 25 5 
18 DHEVASIGAMANI 57 M  22.4 - - 140/96 142 30 100 112 12 24 1.0 0.5 0.5 VBA 8 3 
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19 KUPPAMMAL 50 F - 20   160/100 226 34 160 136 28 48 0.6 0.1 0.5 MCA 5 3 
20 ARUMUGAM 70 M - 26.6 -  150/96 174 38 98 96 10 16 1.3 0.7 0.6 ACA+MCA 28 6 
21 MANGAMMAL 75 F - 20  - 120/80 156 44 96 230 13 24 1.2 0.2 1 MCA 26 6 
22 MUNUSAMY 70 M - 21 - - 110/86 98 28 68 104 12 28 0.7 0.4 0.3 MCA 10 2 
23 AJEETHA BI 80 F - 19.5   130/94 196 36 146 168 34 46 0.9 0.1 0.8 MCA 9 3 
24 SELVARAJ 55 M - 23 - - 110/70 174 60 85 44 10 24 0.7 0.2 0.5 MCA 10 3 
25 SRINIVASAN 57 M  23 - - 120/80 100 26 48 164 11 19 0.7 0.4 0.3 MCA 31 4 
26 KANNAN 75 M - 19.5 - - 110/76 97 24 64 96 10 28 0.9 0.1 0.8 MCA 13 3 
27 PADMA 65 F - 24 - - 120/86 138 30 84 164 10 16 1.0 0.1 0.9 MCA 31 5 
28 SRIDHAR 55 M  21.5  - 140/96 146 32 86 140 16 18 0.8 0.1 0.7 MCA 16 3 
29 BASKAR 39 M  20.4 - - 110/80 146 30 94 104 12 14 0.7 0.1 0.6 MCA 8 4 
30 SYED MEERA 69 F - 26 - - 110/86 114 35 72 56 12 24 0.8 0.4 0.4 MCA 9 1 
31 PAZHANI 48 M - 21  - 120/84 136 39 74 78 18 20 0.9 0.1 0.8 MCA 21 3 
32 CHENGAN 83 M - 28.4 -  150/90 150 34 102 101 10 28 0.9 0.2 0.7 MCA 7 2 
33 SALAMUDEEN 55 M - 23.8   160/90 146 34 80 110 12 24 0.8 0.2 0.6 VBA 15 5 
34 RAVI 60 M - 23.5  - 120/80 160 36 120 94 34 54 1.7 0.3 1.4 VBA 31 4 
35 RAMEEZ B 60 F - 21 -  160/100 194 40 80 104 12 24 0.8 0.1 0.7 MCA 19 3 
36 RAMACHANDRAN 76 M - 28.4 - - 140/96 120 30 64 96 9 12 0.9 0.2 0.7 MCA 25 4 
37 SRINIVASAN 68 M - 22.5 - - 120/70 184 38 124 96 14 14 0.6 0.1 0.5 MCA 6 2 
38 VELU 55 M  20.5 - - 160/100 194 46 120 104 10 22 1.0 0.1 0.9 ACA 30 4 
39 RAJENDRAN 50 M - 23.5 - - 110/80 206 44 142 96 8 10 0.8 0.4 0.4 MCA 11 2 
40 PARVATHI 60 F - 26.6 -  170/106 148 30 90 74 18 16 1.8 0.4 1.4 MCA 27 6 
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41 ANDAAL AMMA 80 F - 19.5 - - 120/70 198 42 100 74 20 30 1.5 0.8 0.7 MCA 30 5 
42 GOPAL 50 M - 24 -  180/100 150 30 108 76 12 22 1.1 0.3 0.8 VBA 22 3 
43 SUBRAMANI 60 M - 22 - - 100/80 124 26 84 142 9 12 0.5 0.1 0.4 MCA 4 1 
44 GOTHANDAM 50 M  23.5 - - 120/76 140 30 94 112 12 10 1.0 0.2 0.8 MCA 30 4 
45 MANIKKAM 84 M - 24 - - 110/80 180 60 92 76 9 18 0.9 0.5 0.4 MCA 8 3 
46 ARUMUGAM 56 M  19 -  140/96 136 50 76 80 11 24 0.8 0.1 0.7 VBA 9 2 
47 KANNAGI 50 F - 22.5 - - 110/70 186 36 80 142 13 28 1.0 0.2 0.8 MCA 26 3 
48 MALLIGA 54 F - 32.5   160/96 184 38 122 112 10 9 1.7 0.3 1.4 VBA 29 5 
49 GOTHANDAM 58 M - 26.7  - 130/84 190 44 108 90 9 12 0.9 0.1 0.8 MCA 10 2 
50 KANNAN 54 M - 23.5 -  104/80 132 32 80 120 6 18 0.5 0.1 0.4 ACA+MCA 7 1 
 
Data Representation Parameters Units Parameters  Units 
  PRESENT TC mg/dL AST IU/L 
- ABSENT HDL mg/dL ALT IU/L 
    LDL mg/dL     
    TG mg/dL     
    TB mg/dL     
    IB mg/dL     
    DB mg/dL     
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MASTER CHART: CONTROLS 
S.No NAME AGE SEX SMOKING BMI DM SHT BP 
LIPID PROFILE LIVER ENZYMES BILIRUBIN 
TC HDL LDL TG AST ALT TB DB IB 
1 ANNAMALI 59 M  24.6  - 110/70 194 46 108 93 40 54 0.9 0.2 0.7 
2 KUPPUSAMY 54 M - 23.4  - 120/70 180 38 118 116 38 43 1.2 0.3 0.9 
3 CHINARASU 48 M - 17.9 - - 110/80 146 42 100 68 14 20 0.4 0.1 0.3 
4 PONNAMAL 76 F - 17.8 - - 130/70 102 36 64 74 9 14 0.7 0.3 0.4 
5 DEVARAJ 50 M - 23.7 - - 126/76 156 37 98 102 16 20 0.4 0.2 0.2 
6 MANIMEGALAI 69 F - 21.6   120/70 206 38 110 126 9 18 0.8 0.3 0.5 
7 KARUNAKARAN 38 M - 30.4  - 110/80 166 39 106 114 12 30 0.8 0.2 0.6 
8 MUTHUSELVAN 58 M  24.6 -  130/90 176 38 112 10 22 30 0.6 0.3 0.3 
9 RAMALINGAM 58 M - 24.8   120/90 174 51 106 91 26 38 0.5 0.1 0.4 
10 SUBBAYA 45 M - 21.8 -  130/86 196 32 134 186 16 19 0.9 0.3 0.6 
11 SIVAKUMAR 42 M  26.8 -  140/90 156 38 102 76 8 17 0.5 0.2 0.3 
12 PURUSHOTHAMAN 70 M - 27.2 -  120/70 154 34 101 104 14 22 0.4 0.2 0.2 
13 PICHAIMUTHU 68 M  22.6 -  110/70 132 32 84 70 6 12 0.8 0.2 0.6 
14 MATHIAZHAGAN 56 M - 22.4 - - 120/80 162 52 84 77 20 24 0.4 0.1 0.3 
15 CHAKRAVARTHY 70 M  20.6 - - 110/80 168 42 102 111 16 22 0.5 0.1 0.4 
16 VISWANATHAN 38 M - 23.8 - - 120/86 140 50 86 71 24 40 1.0 0.5 0.5 
17 THANDAPANI 67 M  20.6 - - 130/80 136 48 84 92 9 16 0.8 0.5 0.3 
18 SUDHAKAR 56 M - 21.2 - - 110/80 190 38 124 96 9 12 0.7 0.3 0.4 
19 TAMILARASI 49 F - 24.8   130/80 199 32 120 102 12 24 0.7 0.3 0.4 
20 THANGAPPAN 68 M - 19.8 -  140/90 146 34 96 121 18 28 0.3 0.1 0.2 
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21 INDIRANI 70 F - 21  - 120/70 186 32 98 100 20 24 1.1 0.5 0.6 
22 SUBBURAYAN 69 M  23.8 - - 120/76 140 48 86 76 20 24 0.6 0.3 0.3 
23 NADIYAMMAL 72 F - 26   140/96 176 34 104 78 6 18 0.7 0.3 0.4 
24 SIVALINGAM 53 M - 22.7 - - 130/80 140 50 76 84 12 16 0.4 0.1 0.3 
25 GURUMOORTHY 54 M - 22.3 - - 110/74 104 37 54 88 14 18 0.4 0.1 0.3 
26 KUMAR 72 M - 24 - - 120/84 179 35 120 94 18 30 0.5 0.1 0.4 
27 SUNDARI 64 F - 16.6 - - 110/70 138 34 88 61 16 20 0.4 0.3 0.1 
28 KANNAN 53 M - 22.7  - 120/80 250 29 104 136 12 16 1.1 0.2 0.9 
29 BALAMURUGAN 38 M  19.4 - - 120/70 144 30 92 102 10 14 0.6 0.3 0.3 
30 MUTHAMMAL 62 F - 23.4 - - 110/74 218 50 138 90 12 18 0.8 0.2 0.6 
31 GURUMOORTHY 50 M - 21.2  - 120/86 180 32 141 116 8 12 0.3 0.1 0.2 
32 CHENGAN 80 M  20 -  140/90 180 40 116 168 6 14 0.7 0.3 0.4 
33 JEYARAJ 59 M - 22.6   130/76 198 42 128 156 48 56 0.4 0.1 0.3 
34 KALIMUTHU 54 M - 21.2   110/70 190 38 144 190 12 20 0.4 0.2 0.2 
35 RASIYA BEGAM 58 F - 23 -  120/86 112 32 70 100 14 18 1.3 0.3 1.0 
36 SUBRAMANI 70 M  21.2 - - 110/70 148 30 94 134 9 22 0.7 0.3 0.4 
37 NATARAJAN 65 M - 19.2 - - 120/84 150 44 89 64 22 40 0.5 0.1 0.4 
38 THANIGACHALAM 53 M - 21.2 - - 110/76 154 42 104 77 16 22 0.7 0.3 0.4 
39 DEVENDRAN 48 M  18.8 - - 130/94 142 46 86 74 14 18 0.4 0.1 0.3 
40 SUBBULAKSHMI 58 F - 29.6 -  110/70 170 36 109 112 42 36 0.9 0.4 0.5 
41 SEETHAMMAL 72 F - 19.2 - - 120/70 130 38 84 66 13 12 0.4 0.1 0.3 
42 DURAI 48 M - 18.2 -  130/86 132 34 82 88 24 40 0.7 0.3 0.4 
43 JEYASEELAN 58 M  18.8 - - 110/74 160 30 96 74 12 38 0.8 0.5 0.3 
44 KANNIAPPAN 48 M - 19.3 - - 110/86 130 40 76 72 9 12 0.5 0.2 0.3 
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45 SATHYAMOORTHY 62 M  17.3 - - 140/86 146 44 64 76 8 14 0.3 0.15 0.15 
46 PANNEER SELVAM 58 M - 19.4 -  110/70 164 50 112 70 12 24 1.0 0.5 0.5 
47 LAKSHMI 56 F - 26.4 - - 130/90 204 38 140 94 6 13 0.4 0.1 0.3 
48 SUNDARAMMAL 55 F - 30.5   150/100 170 44 112 164 60 54 0.6 0.2 0.4 
49 RAJA SEKAR 60 M - 23.3  - 110/70 146 30 92 112 16 18 0.7 0.3 0.4 
50 SRIDHARAN 56 M  29.4 -  130/96 196 44 126 150 9 12 0.4 0.1 0.3 
 
Data Representation Parameters Units Parameters  Units 
  PRESENT TC mg/dL AST IU/L 
- ABSENT HDL mg/dL ALT IU/L 
    LDL mg/dL     
    TG mg/dL     
    TB mg/dL     
    IB mg/dL     
    DB mg/dL     
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÷{õ¯õÎ J¨¦uÀ £iÁ® 
Bµõ´a]°ß ÂÁµ®: குருதி ஊட்டக்குறை பக்கவாத  ந ாயாளிகளின் இரத்த ீர்த்த  
பித்தச்செம்பறெ அளவு (ெீரம் பில்லிரூபின்) மற்றும் அவற்ைின் சதாடர்பிறை ஆரா´யும்   
B´Á¶UøP.  
Bµõ´a] ø©¯®: Aµ_ RÌ£õUP® ©¸zxÁU PÀ¿¶ ©¸zxÁ©øÚ 
÷{õ¯õÎ°ß ö£¯º:      ÷{õ¯õÎ°ß Á¯x: 
£vÄ Gs: 
÷{õ¯õÎ RÌPshÁØÖÒ Pmh[PøÍ () ö\´¯Ä® 
1. ÷©ØSÔ¨¤mkÒÍ Bµõ´a]°ß ÷{õUPzøu²® £¯øÚ²® ¬ÊÁx©õP 
¦¶¢xöPõs÷hß. ÷©¾® GÚx AøÚzx \¢÷uP[PøÍ²® ÷Pmk 
AuØPõÚ ÂÍUP[PøÍ²® öuÎÄ£kzvU öPõs÷hß. 
 
2. ÷©¾® C¢u Bµõ´a]US GÚx ö\õ¢u Â¸¨£zvß ÷£¶À £[÷PØQ÷Óß 
GßÖ®, ÷©¾® G¢u ÷{µzv¾® GÆÂu ¬ßÚÔÂ¨¦ªßÔ C¢u 
Bµõ´a]°¼¸¢x Â»P ¬Êø©¯õÚ E¶ø© EÒÍøu²®, CuØS GÆÂu 
\mh ¤øn¨¦® CÀø» Gß£øu²® AÔ÷Áß. 
 
3. Bµõ´a]¯õÍ÷µõ, Bµõ´a] EuÂ¯õÍ÷µõ, Bµõ´a] E£¯zuõµ÷µõ, Bµõ´a] 
÷£µõ]¶¯÷µõ, KÊ[Sö{Ô ö\¯ØSÊ EÖ¨¤ÚºP÷Íõ G¨÷£õx 
÷Ásk©õÚõ¾® GÚx AÝ©v°ßÔ GÚx EÒ÷{õ¯õÎ £vÄPøÍ C¢u 
Bµõ´a]UPõP÷Áõ AÀ»x GvºPõ» ¤Ó Bµõ´a]PÐUPõP÷Áõ 
£¯ß£kzvUöPõÒÍ»õ® GßÖ® ÷©¾® C¢u |£¢uøÚ {õß 
CÆÁµõ´a]°¼¸¢x Â»QÚõ¾® uS® GßÖ® J¨¦UöPõÒQ÷Óß. B°Ý® 
GÚx Aøh¯õÍ® \®£¢u¨£mh G¢u £vÄPÐ® (\mh§ºÁ©õÚ ÷uøÁPÒ 
uÂµ) öÁÎ°h¨£h©õmhx GßÓ EÖvö©õÈ°ß ö£¯¶À C¢u 
Bµõ´a]°¼¸¢x QøhUP¨ö£Ö® ¬iÄPøÍ öÁÎ°h ©Ö¨¦ 
öuÔÂUP©õm÷hß GßÖ EÖv¯ÎUQß÷Óß. 
 
4. C¢u Bµõ´a]US {õß ¬Ê©Úxhß \®©vUQß÷Óß GßÖ® ÷©¾® 
Bµõ´a]U SÊÂÚº GÚUS AÎUS® AÔÄøµPøÍ uÁÓõx ¤ß£ØÖ÷Áß 
GßÖ® EÖv¯ÎUQß÷Óß. 
 
5. C¢u Bµõ´a]USz ÷uøÁ¨£k® AøÚzx ©¸zxÁ¨ £¶÷\õuøÚPÐUS® 
JzxøÇ¨¦ u¸÷Áß GßÖ EÖv¯ÎUQß÷Óß. 
 
6. C¢u Bµõ´a]US ¯õ¸øh¯ ÁØ¦Özu¾ªßÔ GÚx ö\õ¢u Â¸¨£zvß 
÷£¶¾® _¯AÔÄhÝ® ¬Ê©ÚxhÝ® \®©zvUQß÷Óß GßÖ Cuß -»® 
J¨¦UöPõÒQ÷Óß. 
 
÷{õ¯õÎ°ß øPö¯õ¨£® / ö£¸ÂµÀ øP÷µøP: 
Ch®:     ÷uv: 
Bµõ´a]¯õÍ¶ß øPö¯õ¨£®: 
Ch®:     ÷uv: 
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